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ABSTRACT
An in silico approach to investigate the structural and biochemical basis of the RNA binding
functions of nucleolin
By
Avdar Temmuz San
Advisor: Professor Shaneen M Singh
Nucleolin (NCL) is a stress responsive multifunctional nucleolar protein and accounts for 10% of
the total nucleolar protein content. NCL belongs to the class of RNA binding proteins (RBPs)
that regulate many important cellular processes through their interactions with different RNA
molecules. The dysregulation of RBPs and the RNA metabolism pathways they intersect is a
known driver of tumorigenesis. NCL regulates ribosome biogenesis, chromatin remodeling,
microRNA processing, and gene expression on multiple levels. The RNA-protein interactions of
NCL are primarily driven by its four RNA binding domains (RBDs). NCL is known to interact with
a growing list of primary-miRNA (pri-miRNA) molecules which lead to breast cancer progression
and poor disease prognosis. NCL is also known to interact with both 3’ and 5’ untranslated
region of a group of mRNA molecules, similarly, involved in tumorigenesis and poor disease
outcome. Mechanisms driving NCL-RNA interactions in the context of human cancers are
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currently unknown and this gap in knowledge is further compounded by the incomplete state
of structural information for NCL. In this study, we analyzed NCL-miRNA and NCL-mRNA
interactions in depth with a focus on a subset of RNA molecules that are implicated in cancer.
The lack of structural information for NCL RBD1-4, pri-miRNA, and mRNA UTR molecules was
addressed in this study by the generation of robust 3D models. Interactions of NCL RBDs with
specific RNA molecules were investigated using RNA-protein docking algorithms. These analyses
have revealed a comprehensive map of the NCL-RNA interface for individual RNA pri-miRNA
and mRNA UTRs as well as overall trends in recognition of these RNA species by NCL. Our
results indicate that NCL RBDs 3 and 4 preferentially interact with miRNA molecules whereas a
collaboration between RBDs 1 and 2 and RBDs 3 and 4 is predicted to drive most NCL-mRNA
interactions. We also investigated the oligomerization modes of NCL since oligomerization is
known to regulate certain important RNA binding functions of NCL. Our results revealed that
NCL was predicted to adopt multiple oligomerization modes and each one was predicted to
have different RNA/protein binding capabilities. This theoretical study provides critical clues on
mechanisms driving NCL RBD-mRNA/miRNA target specificity. The in silico predictions derived
from this study further our long-term goal of elucidating the detailed mechanisms of NCL-RNA
interactions in cancer by providing a rational setup for experimental validation of the proposed
mechanism of interaction.
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Chapter 1: Introduction
RNA Binding Proteins (RBPs) and human disease conditions
RNA binding proteins (RBPs) are critical in modulating RNA metabolism that directly influences
numerous important cellular processes, and they are linked with erroneous gene regulation in a
wide range of disease conditions [1]. The human genome codes for more than 3500 RBPs [2] and
the number of RBP-RNA interaction studies are increasing exponentially, thus providing a
growing database that could help us to identify the roles of these proteins in human disease
conditions. The fact that both upregulation and downregulation of RBPs lead to disease
conditions implicates that these RBPs are part of cellular systems that needs fine balancing
interventions by RBPs. Consequently, RBPs are implicated in numerous somatic and mendelian
genetic diseases, impacting multiple organ systems in humans such as metabolic,
neurodegenerative, musculoskeletal, and connective tissue diseases [2]. Large studies conducted
on multiple cancer types from thousands of patients have revealed that expression of hundreds
of RBPs are significantly dysregulated in many cancer types [3] and many have even been
identified as potential cancer drivers [4]. Well established examples of proteins that play a key
role in human cancers include human antigen R (HuR), heterogenous nuclear ribonucloprotein
A1 (HNRNP A1), protein lin-28 homolog B (Lin28B), and nucleolin (NCL) (Table 1) [5]. These RBPs
and their involvement in tumorigenesis have been studied extensively in the literature.
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Table1. List of important RBPs involved in tumorigenesis

Dysfunction in RBPs translate into aberrant control of target RNAs which directly impacts gene
expression at multiple levels. Introduction of this kind of an imbalance is what ultimately drives
pathological phenotypes in RBP driven diseases [5].
RBP-RNA interactions are driven by RNA binding motifs within the RNA binding domains
RBP-RNA interactions are primarily driven by RNA-binding domains (RBDs), highly context
dependent, and often dysregulated in human cancers [20]. Therefore, it is critical to understand
the details of these interactions and the finesse with which RBPs regulate gene expression. RNAbinding ribonucleoprotein motifs (RNPs) within an RBD provide some initial insight into how an
RBP recognizes specific RNA species [21]. Importantly, many RBPs bind the same species of target
RNAs, potentially manifesting a synergistic or competitive physiology [21] in the overall
regulation of the target RNA species. However, detailed molecular mechanisms governing RBPRNA interactions, characteristics of individual RNA binding motifs (RNPs) that dictate specificity
for a particular RNA species, and the interplay of tandemly placed RBDs are all poorly understood.
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RNPs are evolutionarily conserved among many RBPs and each RBD adopts a β1-α1-β2-β3-α2-β4
secondary structure arrangement [22]. The two beta sheets found in the middle of this
arrangement (indicated in bold) are known to interact with RNA and are identified as RNP
motifs: RNP1 is an octameric motif with the following conserved sequence: (R/K)-G-(F/Y)-(G/A)(F/Y)-V-X-(F/Y). RNP2 is a hexameric motif with the following conserved sequence: (L/I)-(F/Y)(V/I)-X-(N/G)-L [23]. These RNP motifs are highly conserved in many RBPs [22].
RNP--RNA interactions are predominantly hydrophobic, and aromatic residues especially play an
important role in the interactions. These aromatic residues drive the interactions through Van
der Waals forces, π-π stacking interactions with nucleotide bases and π-sugar ring interactions
[24]. Van der Waals contacts depend on polarization of the molecules in proximity and vanishes
quickly when interatomic distances increase. π-π stacking interactions are driven by nonoverlapping pi orbitals of aromatic molecules which can be found in a t-shaped or parallel
configuration. The oxygen atom of the 2’ hydroxyl group of the ribose ring mediates all H-bonding
interactions and most π-sugar ring interactions between amino acids and nucleotide bases.
Additional basic residues also form salt bridges with phosphate groups to enhance stability [23] .
In an experimental study [25], Phe and Tyr have been shown to have the greatest affinity to form
Van der Waals contacts to interact with all types of RNA nucleobases. Additionally, basic residues
in these conserved motifs, especially lysine and arginine are known to form hydrogen bonds and
salt bridges with the phosphate groups in the RNA molecules to enhance stability [23]. The role
of aromatic and basic residues is well established in the interactions of HNRNP A1[26-27] and
Lin28B [28] with RNA molecules. This can be seen in Figure 1 which illustrates the details of the
interaction interface for HNRNP1 with mir-18A.
3

Figure 1. Molecular details of the interaction of HNRNP A1 with miR-18A (PDB ID:6DCL). A. Binding
interface residues. Aromatic residues are indicated in red and charged residues are indicated in raspberry
miRNA is in orange. Interacting RNA residues are in deep teal. HNRNPA1 RBD1 is in pale yellow, HNRNPA1
RBD2 in pale cyan, RBD1-2 linker in green. B. Multiple sequence alignment of HNRNP A1 RBD1 and RBD2.
Residues similar in composition are indicated in bold letters. Residues indicated in A are indicated in
colored boxes where the type of interactions are indicated below the alignment

Nucleolin is a biologically relevant, multifunctional RNA binding protein
Nucleolin (NCL) is a multifunctional RBP that is often overexpressed in many cancers and disease
conditions [29]. NCL is involved in myriads of cellular processes that are mostly tied to its
RNA/DNA-binding functions to regulate gene expression that control cell survival, growth, and/or
death. This protein was named nucleolin because of its abundant levels in the nucleolus. Even
4

though NCL makes up close to 10% of total nucleolar protein content, with its numerous
interacting partners and critical functions, localization of NCL can be found in every compartment
of the cell [30,31]. NCL is also heavily post-translationally modified (PTM) such as glycosylation
[32], ADP-ribosylation [33], acetylation [34], methylation [35], sumoylation [36], and
phosphorylation [37]. These modifications regulate NCL functions, and their dysregulation
directly alters major cellular processes leading to tumorigenesis. These PTMs promote NCL’s
cellular localization and functions.
The omnipresent nature of NCL in various cellular compartments except for golgi apparatus and
peroxisome can be explained by the fact that NCL is very sensitive to multiple types of cellular
stress and functions as a stress -sensor and stress-responsive protein. Although NCL mainly
localizes in the nucleolus [38], it is shuttled to other cellular compartments for varied
physiological functions (Figure 2). When cellular stress is induced through heat shock, NCL
relocates to the nucleoplasm to interact with replication protein A (RPA) and sequester it away
from replication foci and allowing DNA repair mechanisms to initiate [38]. Additionally, upon
induction of cellular stress through ionizing radiation (IR) and camptothecin, NCL also relocalizes
to the nucleoplasm by interacting with p53 [39]. This interaction is critical for re-localization of
NCL to the nucleoplasm because it was observed that when the residues on p53 that interact
with NCL were mutated, NCL relocalization to the nucleoplasm was abolished [39]. NCL is known
to interact with the regulatory domain of p53, thus potentially influencing capabilities of p53 to
act as a transcription factor for its downstream targets [39]. NCL is also known to interact with
histone complexes and regulate chromatin transcription [40]. Other studies revealed that NCL
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also migrates to double stranded breaks on DNA and promotes DNA damage response activities
[41].

Figure 2. Subcellular localization of NCL. Darker colored regions implicate higher confidence levels
based on data obtained from Human Protein Atlas [31]. Source: www.genecards.com/NCL [42]

NCL regulates flow of genomic information at multiple levels including messenger RNA (mRNA)
stabilization [43], mRNA decay [18], induction [44] & inhibition [45] of translation, ribosome
biogenesis [46] and microRNA (miRNA) biogenesis [17]. NCL is instrumental in regulating gene
expression during cell survival, growth and cell death as summarized in Figure 3. Therefore, NCL
overexpression in a cancer setting leads to manipulation of these cellular processes vital to the
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survival of cancer cells and NCL overexpression has been linked to worse survival rates in breast
cancer patients [47].

RNA related functions
mRNA stabilization
mRNA decay
Translation

NCL

Ribosome biogenesis

miRNA biogenesis

Protein related functions
Cell cycle checkpoint
activation
Stress sensing
Response
Inhibition of replication

DNA related functions
Chromatin remodeling

Figure 3. Summary of functions of NCL with respect to its interactions with proteins, DNA, and RNA.

Domain Architecture of Nucleolin
As described earlier, NCL is critical to the regulation of cellular homeostasis orchestrated by its
interactions with a multitude of macromolecules including RNA, DNA, and proteins. The
functional and molecular basis of NCL’s intricate and complex interaction network is coded
within its domain architecture. NCL gene (Gene ID: 4691) in humans translates into a 710
amino acid protein that has a predicted mass of 77 kDa but runs at ~ 100-110 kDa on gel
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electrophoresis due to NCL PTMs. Structurally, this 710-residue protein is organized into 3
distinct functional domains (Figure 4):
1) The highly acidic N-terminal domain contains long acidic stretches and the nuclear
localization sequence. The acidic domain is 306 amino acids long and is heavily phosphorylated
during the cell cycle by stage-specific kinases and drives the histone chaperone activity of NCL
[40]. Studies have revealed that NCL mutated at major phosphorylation sites on its N-terminal
causes impairment of cell cycle progression in proliferation [48], and improper regulation of the
DNA Damage response [49]
2) The glycine and arginine-rich (GAR/ RGG) C-terminal domain is 64 amino acids long and is
required for interactions of NCL with ribosomal proteins [50]. This domain is also known to
interact with the tumor suppressor p53 protein [51] and is implicated in non-specific
interactions with RNA [52]. Additionally, this domain is known to be able to anneal single
stranded DNA molecules [53] and interact with G-quadruplex DNA structures [54].
3) The central region is organism specific and is composed of two to four distinct RNA-binding
domains and is 340 amino acids long in humans. This domain is critical for interactions of NCL
with different RNA molecules [54]. Most eukaryotic species, including plants and yeast, contain
only two RBDs in NCL protein. NCL in yeast and plants are also involved in rRNA biogenesis.
Interestingly, RBD1-2 in plants and yeast displays high sequence similarity with RBD1-2 in
animals and both regions are responsible for the same function in their respective species.
Surprisingly, NCL from Dictyostelium Discoideum uniquely possesses an odd number of RBDs
(three RBDs) suggesting a unique RNA binding profile in this organism (Singh Lab, unpublished).
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NCL RBDs have evolved in vertebrates, including humans, to an increased (four) number of
RBDs where RBDs 3 and 4 are unique to these species [55].
It is also well-established that RBDs 1 and 2 are sufficient for certain NCL-RNA interactions,
specifically binding to rRNA [46] and certain mRNA [18,19] molecules. The newly emerged RBD3
and 4 domains suggest potential novel functions of NCL in these higher organisms. However, in
contrast to RBDs 1 and 2, RBDs 3 and 4 have remained overlooked and understudied. There is
only one study that has investigated RBD3 and RBD4 and suggests that they are involved in
annealing of single stranded DNA molecules in conjunction with the RGG domain [56]

Figure 4. Domain architecture of nucleolin in plants, yeast, D. Discoideum, and animals. The RBDs are
indicated with colored boxes in the central region.

NCL-RNA interactions
NCL regulates gene expression by binding both coding (mRNA) and non-coding RNA species
(rRNA, miRNA, and long non-coding RNA) as illustrated in Figure 5. NCL-mRNA interactions
mediated by its RBDs influence mRNA turnover rate by directly promoting mRNA decay [18,19].
NCL is also capable of enhancing translation by interacting with Poly A binding protein (PABC)
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[18] or promoting internal ribosome entry site (IRES) mediated translation [44]. NCL also
interacts with long non-coding RNA (lnc-RNA). These interactions also have implications in RNA
localization activities of lncRNA PVT1 [57] and lncRNA SNHG1 [58]. Multiple studies have
established that NCL interacts with RNA preferentially through stem loop structures and often
binds to apical loops [19,46]. Besides loop structures, NCL is also known to interact with AU-rich
elements (ARE) [43,59]. Additional studies have revealed that NCL also has an affinity for G-rich
sequences [60,61] and G-quadruplex structures [18,62]. Interestingly, NCL also interacts with
CU-rich regions in certain mRNA molecules to regulate their expression levels [63]. All these
serve as signature sequence or structural motifs for NCL-RNA affinity. In fact, a 7-10 nucleotide
(nt) long G-rich stem-loop structure called nucleolin recognition element (NRE) found in preribosomal RNA, establishes a primary role of NCL in processing rRNA [64]. Similarly, NCL also
demonstrates high affinity for the 11 nt single stranded evolutionary conserved motif (ECM)
that contains the sequence UCCCGA, found 5 nt downstream of the pre-rRNA processing site
[65].
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Figure 5. Summary of the interactions of NCL with different types of RNA

The only available structural study of NCL-RNA interactions has provided some insights into the
molecular details of NCL-rRNA interactions [65]. The crystal structure RBD1-2 (PDB ID: 1FJE)
shows that NCL binds with high affinity to stem-loop structure called nucleolin recognition
element (NRE) found in pre-ribosomal RNA and utilized by NCL for ribosomal RNA (rRNA)
recognition. This region contains the sequence motif UCCCGA that is critical for recognition by
NCL RBD1 and RBD2(RBD1-2). These interactions are predominantly driven by residues on RNP
motifs that include aromatic and polar charged residues (Phe4, Arg35, Tyr45 on RBD1 and
Glu112, Arg114, Tyr127 on RBD2) along with additional basic residues from linker region
(Arg81, Lys82) between RBD1-2 (Figure 6).
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Figure 6. NCL-rRNA binding mode as revealed by the crystal structure of 1FJE. RBD1 is colored marine
blue and RBD2 is colored deep salmon. The linker region connecting RBD1 to RBD2 is colored neon
green. Interacting RNA and protein residues are indicated in deep teal and yellow, respectively.

Significance of this study
Although the current literature provides valuable clues regarding sequence specificity of NCL
RBDs in NCL-rRNA interactions, interactions of NCL with other RNA species are still extremely
understudied. Additionally, molecular mechanisms driving these interactions have not been
investigated in sufficient detail due to the lack of available experimentally resolved structural
information. Such an investigation is warranted because of the complex nature of NCL-RNA
interactions and especially because the outcomes of these interactions may lead to
enhancement of tumorigenesis in many human cancers. Identification of RNA binding
12

signatures remains technically challenging and context dependent. Elucidation of these
mechanisms requires identification of both RNA and protein residues driving these interactions.
Verification of these residues is classically done through mutational studies in a wet-lab setting.
Although the results of these studies would provide critical information, conducting these
experiments without any preliminary guidelines are both time and resource consuming
endeavors. State of the art computational analyses provide a powerful means for addressing
some of the gaps in knowledge that currently exist in RBPs-RNA interactions. This dissertation
aims to address this gap in structural information by utilizing computational tools and
generating 3D models and in addition to generate predictions regarding molecular mechanisms
driving NCL-miRNA and NCL mRNA interactions in the context of cancer. These predictions can
be then validated with rationally designed experiments based on results of our computational
findings. Ultimately, information derived from this predictive study could provide structural
clues that are much needed in development of a therapeutical intervention that targets
elements of the molecular mechanisms of NCL-RNA interactions promoting tumorigenesis in
cancer.
The following chapters of this dissertation address the three specific aims of the study.
Specific Aim 1: Elucidation of miRNA binding residues on NCL RBDs
NCL’s role in miRNA biogenesis is established for certain miRNA molecules and there is evidence
that they physically interact with NCL. In other cases, expression of a variety of miRNA clusters
is strongly correlated with NCL levels. Despite these advances, studies assessing the structural
details of these interactions are limited and highly needed. Only the crystal structures of RBD1-
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2 in tandem are available in the literature along with individual and misannotated structures of
RBD3 and RBD4. Partial structures of both NCL and RNA molecules are not sufficient to
generate much needed structural information on how these molecules interact with each
other. We hypothesized that NCL RBD3-4 have evolved in animals to mediate NCL-miRNA
interactions. This chapter of the dissertation addresses the gap in structural information that
could help with elucidation of NCL-miRNA interactions in breast cancer. Therefore, theoretical
three-dimensional models of NCL RBDs and miRNA molecules were generated. These models
were used in RNA-Protein docking algorithms to produce predictions to identify key residues
that make up the interaction interphase. The results reveal the role of NCL RBD 3-4 in miRNA
recognition and we propose potential binding NCL-miRNA binding models that provide clues
about how NCL might be involved in biogenesis of miRNA molecules that promote
tumorigenesis in breast cancer.
Specific aim 2: Investigation of NCL-mRNA interactions
NCL is an important factor in the mRNA regulation process and is directly related to mRNA
translation rates. NCL accomplishes this by interacting with both coding regions and
untranslated regions (UTRs). Studies have revealed that interactions of NCL with regions of
certain mRNA molecules could lead to conditions that promote tumorigenesis. These UTRs
often contain multiple apical loop structures or sequence specific elements that NCL may
target, but the details of the biochemical nature of these interactions remain unexplored. We
hypothesized that RBD1-2 are responsible for NCL-mRNA UTR interactions based on previous
studies that suggest the involvement of RBD1-2 in NCL-p53 mRNA binding. A similar protocol of
in silico modeling, docking and analysis as in Aim 1 were used to generate possible interaction
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scenarios. These scenarios were used to identify both RNA and protein residues driving these
interactions. The information derived from this investigation was then compared with existing
information to generate predictions of NCL-mRNA UTR binding modes. Our findings are detailed
in Chapter 3 which negates our hypothesis that RBD 1-2 are the primary drivers of NCL-mRNA
UTR interactions. The findings from this aim provides context to the limited information on
NCL-mRNA UTR interactions in human cancers and provides valuable building ground for
further studies designing therapeutical interventions.
Specific Aim 3: Investigation of NCL domain-domain interactions in oligomerization
Previous research demonstrates the importance of NCL domains in its ability to oligomerize.
NCL oligomerization is a domain specific function, and it is NCL RBD-dependent. There are no
modes of oligomerization described for NCL. NCL oligomerization is important because certain
regulation functions of NCL depends on its ability to oligomerize. NCL is predicted to dimerize in
the presence of certain molecules such as p53 3’ UTR to suppress its translation but the
mechanisms driving these interactions are understudied. Additionally, NCL regions and residues
important for these interactions have not been elucidated. The absence of a known structure
for full length NCL stands as the greatest challenge to elucidate these interactions. We
hypothesized that NCL RBD linker regions are responsible for oligomerization. This chapter
focuses on dissecting specific interface residues that are involved in NCL-NCL oligomerization
and generating predictions on possible oligomerization modes. The predicted oligomerization
model suggests a role for the RBDs including the linker regions as well as the RGG domain in
mediating dimerization of NCL. Our results have allowed us to identify residues and
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biochemical/biophysical features that are important for this interaction. Additionally, we also
probed the interaction of the p53 mRNA 3’ UTR with the dimerized NCL complex.
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Chapter 2: NCL-miRNA interactions
Mechanism of microRNA processing in higher vertebrates
MicroRNAs belong to the family of non-protein coding RNA that regulate expression of certain
genes. In its mature single stranded form, miRNA binds to 3’ UTR of mRNA sequences in the
cytoplasm and prevent their translation by ribosomes. miRNA is initially transcribed by RNA
Polymerase II [66]. These primary transcripts (pri-miRNA) are processed by Drosha, a
ribonuclease, in the nucleus [67]. After the discovery of its partner DGCR8, which is another
RBP, these 2 proteins have been identified as the microprocessor complex and are responsible
for processing of pri-miRNA into precursor miRNA (pre-miRNA) by removing the cap and the
poly-A tail [68]. Pre-miRNA is then transported to the cytoplasm by exportin 5, a shuttle protein
[69]. The pre-miRNA is processed further by Dicer into the RISC loading complex with the help
of Tar RNA binding protein (TRBP) and Argonaute2 (Ago2)[70]. This mature miRNA is then
coupled with the RNA-induced silencing complex (RISC) [71] that allows it to be escorted
specifically to its complementary target sequence to suppress translation of mRNA transcripts
and effectively regulate gene expression (Figure 7). Translation repression can be achieved by
binding of miRNA to 3’ UTR region of the target RNA, and therefore physically blocking the
ribosome from conducting translation in 5’ to 3’ direction. miRNA biogenesis pathways are very
often manipulated for the benefit of cancer cells. By controlling gene expression through
miRNAs, cells can manipulate important cellular processes including proliferation, cell-cycle
checkpoints, cell death, and metastasis, all of which are hallmarks of cancer [72].
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Figure 7. Summary of miRNA processing steps and proteins associated with every step

NCL-miRNA interactions and roles of NCL in miRNA processing
Numerous studies in the last decade have focused on NCL-miRNA interactions and they
highlight another route and mechanism through which NCL plays an important role in
maintaining cellular balance. These studies together suggest that NCL can interact with primiRNA molecules: RNA immunoprecipitation experiments have demonstrated that NCL
interacts with pri-miR-15a and pri-miR-16 in HEK293 cells and knockdown of NCL resulted in a
decrease of mature miR-15a and miR-16 levels in MCF-7 breast cancer cells [17]. Another
experimental study revealed that NCL directly interacts with pri-miR-21, pri-miR-103, pri-miR221, and pri-miR-222 in Hela cells. Further, it was observed that knockdown of NCL in MCF-7
breast cancer cells resulted in disruption of this interaction, which in turn resulted in reduction
of mature levels of these miRNAs [73]. The roles of NCL in miRNA biogenesis is constantly
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evolving with new examples of NCL-miRNA interactions emerging constantly in the literature.
Some of these miRNAs are shown to directly interact with NCL-RBDs (Table 2; 17,73). Several
other miRNAs and miRNA clusters are predicted to interact with NCL although the mechanism
has not been elaborated. Transcriptomic studies point to reduced expression levels of certain
miRNA molecules, and clusters upon NCL depletion [74,18] and NCL phosphorylation [51].
Additional studies in transgenic mice [52] similarly demonstrated that NCL overexpression
results in differential expression of certain miRNA clusters. Gene ontology analyses have
revealed that these miRNA clusters are heavily involved in regulation of proliferation, metabolic
signaling pathways, cell differentiation and migration and even cholesterol synthesis [50].
Taken together, all these studies clearly demonstrate that NCL is intricately involved in
numerous critical cellular processes and instrumental in maintaining a fine balance in regulation
of these processes. NCL is directly involved in the synthesis and regulation of miRNA molecules.
Indeed, it was discovered that NCL affects miRNA biogenesis [17] by physically interacting with
the microprocessor complex (MPC), which is responsible for processing of pri-miRNA into premiRNA. This association was further corroborated by co-immunoprecipitation experiments with
MPC active components, Drosha and DCGR8 [17]. More Importantly, these interactions have
cellular consequences, and their impacts range from altered rates of proliferation, avoiding
apoptosis to tumor suppression mechanisms. Therefore, as NCL is overexpressed in human
cancers, it is highly likely that deregulation of all these processes through NCL is directly related
to tumorigenesis and cancer progression.
Table 2. Summary of documented NCL-miRNA interactions from the literature
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miRNA family / clusters

Interaction Type

Cell/Tissue Type (Ref #)

miR-15a, miR-16

Experimental/RNA

HeLa cells / Breast cancer (17)

Immunoprecipitation (RNA IP)
MiR-21, miR-221, miR-222, miR-

Experimental/RNA IP, Checking

HeLa cells / Breast cancer (73)

103

miRNA levels after NCL depletion

miR-130a, miR-301a

Predicted/Checking miRNA target

Ovarian Cancer, Adenocarcinoma

levels after NCL depletion

(18)

Clusters of miR17-92, 15a-

Predicted/Transcriptome analysis

HeLa Cells (74)

16,221-222, 30, let-7, mir-155

to check expression levels of
miRNA when NCL was depleted

miR-93, miR-484

Predicted /Checking miRNA target Human Umbilical Vein Cells
levels after NCL phoshporylation

(HUVEC) (75)

miR-223, miR-214, miR-146b,

Predicted/ Transcriptome analysis

Transgenic mice (76)

miR-199a-5p, miR-208b, miR-

to check expression levels of

29a, miR-146a, miR-34a, miR-

miRNA when NCL was

690, miR-582-5p, miR-135a,

overexpressed

miR-145, miR-218
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Differences in pri-miRNA processing in higher vertebrates versus plants/yeast and its
potential ramifications for NCL’s role in miRNA biogenesis.
Processing of miRNA molecules by the MPC begins in the nucleus and is then further processed
in the cytoplasm in animals. However, miRNA processing in plants proceeds with significant
differences when compared to miRNA biogenesis in animals: Processing of both the pri-miRNA
and pre-miRNA in plants take place in the nucleus and the proteins involved in the process differ
as well. In plants, the processing of both miRNA precursors is conducted by a Dicer-Like1 (DCL-1)
protein in concert with another helper protein, hyponastic leaves1 (HYL-1) [77]. A similar
mechanism also exists in Dictyostelium Discodeium, a slime mold species, where the double
stranded RNA (dsRNA) binding protein RbdB and dicer homolog DCR1 are involved in processing
of pre-miRNA molecules [78]. While the MPC processes pri-miRNA in animals in a collaboration
with NCL, many different proteins conduct the same function in plants and yeast, replacing MPC
and NCL (Figure 8). These proteins undertake the dual role of holding the RNA tight by a double
stranded RNA binding protein and making two single stranded cuts on the RNA strand by an
RNAse-like protein. NCL is neither a homolog of these proteins nor does it interact with them.
This suggests that NCL may not be involved in this process both in plants and yeast. Interestingly,
NCL homologs from plants/yeast possess only RBD1-2 and lack RBD 3-4. NCL is known to interact
with the active components, Drosha and DCGR8 in the microprocessor complex [17] and the
emergence of NCL-RBD3-4 in higher vertebrates coincides with the roles of NCL in miRNA
processing. We, therefore, propose that the emergence of NCL-RBD3-4 in higher vertebrates
coincides with the NCL role in miRNA processing in evolution and that RBD3-4 possess

21

sequence/structural determinants in NCL protein that specifically recognize miRNA precursor
molecules in NCL protein.

Figure 8. Comparison of proteins actively involved in pri-miRNA processing in higher vertebrates with
plants/yeast. Hyponastic leaves1 (HYL-1) and RbdB function as dsRBDs whereas Dicer-like1 (DCL1) and
Dicer-1 function as RNAses.

HNRNP A1-miRNA binding serves as a model for RBP- miR interactions
Heterogenous nuclear ribonucleoprotein A1 (HNRNP A1) is a well-studied RBP and is known to
interact with a wide range of RNA species including processing of pri-miRNA molecules in
collaboration with MPC proteins, similar to NCL. HNRNP A1 houses 2 RBDs, each containing both
the RNP1 and RNP2 motifs. A structural study revealed that HNRNP A1 interacts with pri-miR-18
molecules which in turn promotes the processing of this miRNA molecule. This interaction serves
as a model for RBD-RNA interactions and is especially relevant for studying NCL-miR interactions
because both proteins interact with miRNA and HNRNP A1 RBDs share high sequence similarity
with NCL (Figure 9). The experimentally resolved structure of HNRNPA1 in complex with pri -mir18 (PDB ID: 6DCL; 26) has detailed the residues driving the interaction. As shown in Figure 9, it is
primarily the aromatic and charged residues on RNP motifs (Phe17 of RNP2 and Arg55, Phe57,
Phe59 of RNP1 on HNRNP A1 RBD1 & Phe108 of RNP2 and Arg146, Phe148, Phe150 of RNP1 on
HNRNP A1 RBD2) that drive these interactions. It is also interesting to note that both RBDs
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interact with the same sequence motif (UAG) on the RNA. This mode of interaction not only
emphasizes the importance of RNP motifs in RBP-miRNA interactions but also reveals that some
residues from beta 2 strand (Glu85, Arg87) are also part of the interaction interface.

Figure 9. Multiple sequence alignment of HNRNP A1 (PDB:6DCL) and NCL RBDs. Residues from HNRNP
A1 RNP motifs involved in HNRNP A1-miR18a interactions are indicated in yellow boxes. Beta strands and
RNP motifs are indicated below the alignment. Conserved residues are boxed in black (identical residues),
or indicated in bold font (similar residues).

Current state of knowledge of NCL-miR interactions, unknowns, and goal of this study
The focus of this study was to elucidate the selective preference of specific NCL RBDs and RBD
residues involved in the recognition of miRNAs using an in-silico approach since current structural
information available in the literature is insufficient for the elucidation of these mechanisms. The
fact that interactions of NCL promotes biogenesis of certain miRNA molecules and these miRNA
molecules are known to dysregulate cellular processes important for survival and growth is
another reason why it is critical to decipher the molecular mechanisms and residues driving these
interactions. Structural modeling and in silico analysis tools provide valuable information to fill in
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the knowledge gaps and provide a cost effective and rational entry point in experimental design.
Ultimately, the insights from this study can lead to future studies for identifying new drug design
targets to regulate NCL functions in gene expression during tumorigenesis.
Methods
A flowchart summarizing the general protocol of the present study with the various tools used to
analyze

NCL-miRNA

interactions

(discussed

in

detail

later)

is

shown

below.

Figure 10. Flowchart depicting the methods and tools utilized in this chapter. Individual steps and
programs/algorithms utilized in those steps are indicated in blue and white boxes, respectively

Sequence analysis and generation of 3D models of NCL-RBDs
Since only partial structural information for NCL-RBDs is available, robust 3D models of all 4 NCL
RBDs (RBD1-4), and RBD3-4 were built; structural information for RBD1-2 in tandem (PDB ID:
2KRR) [79] and for individual RBDs (PDB ID: 1FJ7 & 1FJC, respectively) [80] is available for human
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NCL. The possibility that RBD 2-3 may form a functional RBD tandem pair was also investigated
by modeling RBD 2-3. The human NCL sequence available from NCBI database [81] was analyzed
for its domain architecture using the programs SMART [82], Pfam [83], Uniprot [84], and Interpro
[85] to confirm the domain boundaries of the individual RBDs accurately as well as to identify any
potential sequence motifs of relevance. The multiple sequence alignment tool Clustal Omega [86]
was used to align the NCL-RBDs with HNRNPA1 RBDs to identify conserved residues. The multiple
sequence alignment was visualized using the alignment editor Espript3 [87].
Delineated tandem domain pairs were modeled using both template-based methods
(Swissmodel [88] Intfold [89], Phyre2 [90]) and ab initio modeling approaches (Robetta [91],
QUARK [92], and I-TASSER [93]) to generate structural models. To identify high quality models,
the constructed models were rigorously evaluated by model verification programs including
Verify3D [94], VoroMQA [95], Prosa-web [96], and ProQ3 [97] and correlation of their biophysical
and structural properties with experimental observations. Top models were then refined using
ModRefiner [98] and SCWRL4 [99] and then re-evaluated. ModRefiner first modifies the protein
side chain packing by adding atoms and improves the structural quality of reconstructed models
by energy minimization procedures. SCWRL4 focuses on side chain refinements to improve the
models. Top scoring models were chosen for further analysis.
Generation of 3D models of miRNA implicated in interactions with NCL
Structural information of known oncogenic miRNA molecules interacting with NCL is unavailable
in the databases. The limited structural data available in the protein databank for the 6 miRNA
molecules under study corresponds to either partial pre-miRNA structures or apical loops (PDB
ID: 2MNC, 5UZT) [100,101] and neither provide structural information for the complete pri25

miRNA structures. Since structural information for miRNA molecules that interact with NCL in the
context of breast cancer (pri-miR-15a, pri-miR-16-1, pri-miR-21, pri-miR-103a, pri-miR-221, and
pri-miR-222) is either unavailable or limited to partial structures, we generated and utilized 3D
models. Therefore, all pri-miRNA molecules were modeled using the primary sequences of
miRNA stem loop structures obtained from miRbase [102]. The secondary structure of these
miRNA molecules was predicted using various programs including RNAStructure [103], RNAFold
[104], MC-Fold [105], CentroidFold [106], and SPOT-RNA [107]. Although all these tools provide
predictions based on experimental data found in databases, some of the newer methods such as
CentroidFold and SPOT-RNA also utilize machine learning in making these predictions. All of the
predicted secondary structures (dot bracket format) obtained from these tools were input into
the RNA modeling software including RNAComposer [108], ifold2 [109], RNAfold3 [110], 3DRNA
v2 [111] and simRNAweb [112] to obtain 3D models of these miRNA molecules. The generated
models were evaluated for their structural quality using MolProbity [113]. The top models were
refined using RNAfitme [114], a program that reconstructs nucleobases and nucleosides while
keeping the sugar phosphate backbone fixed and aiming to reduce steric clashes.
Prediction of motifs involved in NCL-miRNA interactions
NCL-miRNA interactions were investigated using the protein-RNA docking software HDOCK [115]
and NPDock [116]. Both programs employ a rigid body docking approach followed by scoring and
clustering of structures with the lowest minimum energy followed by refinement of the results
through Monte Carlo simulations. Both the programs are considered the top ranked algorithms
for protein-RNA docking and score well in benchmarks. After completing the refinement steps,
the top 3 models for RBD1-4 were chosen to be docked with every generated miRNA model (1
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model from each miRNA except for mir-21 and mir-16-1, 8 in total). HDOCK yields 10 scenarios,
NPDOCK yields 2 on average. Therefore 240(10x3x8) + 48(2x3x8) =288 scenarios were used to
identify binding modes, as well as the interacting residues from both molecules, and the type of
interactions. Then all the recorded residues and the type of interactions were counted to identify
the most frequently predicted residues from the docking scenarios. Further, it was investigated
which of these highly predicted NCL residues could potentially form an RNA binding motif.
Residues and motifs that were predicted with a high frequency were then mapped onto the
multiple sequence alignment of all RBDs to investigate their locations on their respective RBD
and compared with expected residues based on prior studies.
The docking results were visualized in PyMOL [117] and the interactions mapped out using
Nucplot via the PDBSum webserver [118]. The key interacting residues in the NCL-RBDs were
identified based on the 10 top scoring scenarios from each docking run. Besides the NCL residues,
most frequently predicted RNA residues on every miRNA molecule from all docking scenarios
were also counted and mapped on their three-dimensional structure to identify any specific RNA
motif that could potentially interact with NCL. By parsing the information from both analyses,
location-specific potential NCL-RNA binding modes were identified. These binding modes were
then compared to the known molecular details of the MPC complex in order to predict possible
cooperation models between NCL and MPC. These residues were compared with putative
residues of NCL-RBDs identified using catRAPID [119], a program that predicts binding propensity
of a protein sequence to a given RNA sequence by measuring physicochemical properties and
shape complementarity. Additionally, docking experiments were also performed using NCL
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mutants generated by in silico mutagenesis of key residues of NCL identified to be important in
NCL-miRNA interactions in the current study.
Results
3D structural models of NCL RBD1-4, RBD3-4 and specific miRNAs provide a complete structural
picture needed to study NCL-miRNA interactions
The tandem pair of NCL RBD1-2 structure is experimentally resolved (PDB ID: 2KRR) [79] and well
characterized for its interactions with various rRNA [86] and mRNAs [18,19]. While individual
crystal structures of RBD3 and RBD4 are available, albeit misannotated (PDB IDs: 2FC9 & 2FC8
[120]), the functional role(s) of the NCL RBD3-4 tandem pair remain unresolved and unexplored.
Structural information for all the RBDs in NCL are critical to fully understand the mechanistic
details about various RNA-targets of NCL and the key features that render target-specificity. Lack
of structural details on RBD1-4 as a whole and the RBD3-4 tandem pair, pose limitations in
dissecting the specificity with which NCL binds to a wide-range of RNA species and plays pivotal
role/s in pathophysiology. Therefore, structural models of NCL-RBDs and miRNA molecules
generated using template based and ab initio approaches were analyzed to identify robust
models with high evaluation profiles (Tables 3, 4 and 5) to bridge the gap in NCL-RBD structural
information.
Table 3. Evaluation and refinement of RBD1-4 models. RBD1-4 models were evaluated by the structural
quality control programs listed in the columns. Top scoring models from each group for every program
are indicated in bold. Models which obtained a high score overall were selected for refinements.
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RBD1-4

VERIFY3

VoroMQA

ProSA

ProQ3

Candidat

Top

D

(Global

Web

(Global

e models

ranked

(residues

score)

(Z-

score)

with 1D-

model

score)

3D score
above
0.2 %)
Model Evaluation
RBD1-4 SWISS
5VSU.1A

92.63

0.381

-6.65

0.471

X

6ASO.1A

90.86

0.362

-6.31

0.419

M1

62.24

0.403

-7.75

0.350

M2

57.35

0.392

-7.6

0.360

M3

65.19

0.387

-7.11

0.449

M4

80.88

0.314

-4.88

0.510

M5

88.53

0.312

-5.00

0.517

X

M1

85.29

0.361

-6.55

0.408

X

M2

85.29

0.320

-6.21

0.398

M3

81.47

0.328

-6.44

0.489

X

RBD1-4 Intfold
X

RBD1-4 I-TASSER

X
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RBD1-4 Phyre

73.24

0.294

-5.54

0.421

M1

95

0.414

-7.22

0.490

M2

99.71

0.423

-7.2

0.486

M3

99.71

0.385

-7.08

0.341

M4

92.06

0.401

-7.1

0.480

M5

100

0.408

-6.79

0.501

SWISS 5VSU MR

93.51

0.361

-6.36

0.483

ITASSER M1 MR

91.47

0.358

-6.31

0.404

ITASSER M3 MR

85.88

0.326

-6.5

0.389

Intfold M1 MR

100

0.414

-8.13

0.338

Intfold M5 MR

86.18

0.374

-5.6

0.509

Robetta M1 MR

93.24

0.380

-7.15

0.452

X

X

Robetta M5 MR

100

0.386

-6.76

0.486

X

X

SWISS 5VSU Scwrl

88.50

0.368

-6.65

0.456

ITASSER M1 Scwrl

77.94

0.311

-6.55

0.432

ITASSER M3 Scwrl

77.35

0.333

-6.44

0.453

Intfold M1 Scwrl

59.88

0.402

-7.75

0.374

Intfold M5 Scwrl

79.12

0.332

-5.00

0.506

Swiss MR Scwrl

92.63

0.364

-6.36

0.479

RBD1-4 Robetta
X

X

Refinement of top
models
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Robetta M1 Scwrl

95

0.377

-7.22

0.448

Robetta M5 Scwrl

100

0.383

-6.79

0.440

Table 4. Evaluation and refinement of RBD34 models. RBD34 models have been evaluated by the
structural quality control programs listed in the columns. Top scoring models from each group for every
program are indicated in bold. Models which obtained a high score overall were selected for
refinements.

RBD34

MODELS VERIFY3D

VoroMQA

ProSA

ProQ3

Candi

Top

(residues with

(Global

Web

(Global

date

ranked

1D-3D score

score)

(Z-score)

score)

model

model

above 0.2 %)

s

Model
evaluation
Swissmode 6DCL.1A

100

0.389

-6.37

0.619

l

4PKD.1B

89.44

0.344

-5.92

0.585

QUARK

M1

98.76

0.341

-5.85

0.416

M2

99.3

0.348

-6.02

0.549

M3

100

0.360

-5.28

0.549

M4

100

0.327

-5.68

0.493

M5

100

0.369

-5.68

0.569

X

X
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I-TASSER

IntfoldM5

M1

100

0.391

-7.44

0.572

M2

90.06

0.371

-6.42

0.623

M1

100

0.382

-6.63

0.650

M2

100

0.381

-6.83

0.579

M3

100

0.397

-7.04

0.653

M4

98.14

0.370

-6.45

0.609

M5

98.14

0.370

-6.45

0.609

RBD34

47.50

0.200

-4.49

0.390

M1A

100

0.433

-7.1

0.724

M1B

100

0.437

-7.2

0.700

M2A

100

0.433

-7.32

0.705

M2B

100

0.428

-7.35

0.695

M3A

100

0.410

-6.9

0.644

M3B

100

0.420

-6.96

0.684

M4A

100

0.424

-7.07

0.705

M4B

100

0.424

-7

0.684

M5A

100

0.444

-7.03

0.713

M5B

100

0.437

-7.39

0.687

X

X

Phyre
Robetta

X

X

Refinemen
t of top
models
32

Scwrl4

Intfold

99.38

0.403

-7.04

0.609

M3

100

0.386

-7.44

0.574

ITASSER

93.79

0.370

-6.37

0.616

M1

99.38

0.331

-5.68

0.530

6DCL.1A

100

0.433

-7.1

0.724

QUARK

100

0.444

-7.03

0.713

X

Modrefine

6DCL.1A

100

0.409

-7.94

0.667

X

X

r

MR

100

0.372

-5.86

0.607

Quark

100

0.415

-7.07

0.617

m5 MR

100

0.417

-7.5

0.577

Intfoldm 100

0.440

-7.06

0.652

X

X

3 MR

0.441

-7.08

0.642

X

X

100

Table 5. Evaluation and refinement of miRNA models. All miRNA models were evaluated by MolProbity
for structural integrity. For every category of evaluation, a lower score indicates a higher quality model.

miRNA models

Clash

Probable

Bad backbone

Bad

Bad

Top

score

wrong sugar

conformations

bonds

angles

ranked

puckers

model

miR-15a models
RNACompstd

22.49

1

15

0

0
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RNAFold

22.49

0

15

0

0

MCSYM

17.24

1

4

0

0

Centroid

27.36

1

20

0

0

SPOT-RNA

17.62

1

16

0

0

RNAStructure

22.49

1

15

0

0

RNACompstd

20.05

2

17

0

0

RNAFold

16.18

2

13

0

0

MCSYM

13.01

2

5

0

0

Centroid

20.05

2

17

0

0

SPOT-RNA

12.66

2

9

0

0

RNAStructure

16.18

2

13

0

0

RNACompstd

19.98

0

11

0

0

RNAFold

21.29

0

9

0

0

X

MCSYM

20.85

0

7

0

0

X

Centroid

19.98

0

11

0

0

SPOT-RNA

49.96

1

9

10

27

RNAStructure

16.51

2

12

0

0

19.32

4

24

0

0

X

miR-16 models

X

X

miR-21 models

miR-103 models
RNACompstd

34

RNAFold

15.69

4

17

0

0

MCSYM

14.49

1

9

0

0

Centroid

18.91

3

18

0

0

SPOT-RNA

22.94

3

16

0

0

RNAStructure

16.9

4

19

0

0

RNACompstd

25.07

2

28

8

6

RNAFold

25.93

2

25

8

6

MCSYM

70.66

4

18

17

44

Centroid

20.23

3

27

0

0

SPOT-RNA

17.09

3

21

0

0

RNAStructure

24.79

2

28

8

6

RNACompstd

17.69

2

14

0

1

RNAFold

17.69

2

14

0

1

MCSYM

18.54

2

22

0

0

Centroid

14.27

1

20

0

0

SPOT-RNA

17.69

3

19

0

0

RNAStructure

17.69

2

14

0

1

13.58

1

12

0

0

X

miR-221 models

X

miR-222 models

X

mir-155
RNAFold

35

RNAFold NB

10.66

0

12

0

0

RNAFold NS

3.39

0

12

8

48

Centroid

18.91

1

10

0

0

Centroid NB

13.08

0

10

0

0

Centroid NS

4.36

0

10

6

50

MCSYM

19.4

2

14

0

0

MCSYM NB

13.08

0

14

0

1

MCSYM NS

3.88

0

14

3

44

SPOTRNA

18.43

0

10

0

0

SPOTRNA NB

7.27

0

10

0

1

SPOTRNA NS

1.94

0

10

13

56

X

Figure 11 shows that the superposition of the top ranked RBD1-4 (Figure 11A) and RBD3-4 (Figure
11B) models with the existing individual crystal structures of RBD1, 2, 3 and 4 overlays very well
with minor deviations in the loop regions.
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Figure 11. NCL tandem RBD models display high structural similarities with existing individual NCL-RBD
crystal structures. A. Superposition of the modeled RBD1-4 (pale green) with individual crystal structures
of NCL RBD1 (PDB ID: 1FJ7 ;marine blue), RBD2 (PDB ID: 1FJC deep salmon), RBD3 (PDB ID: 2FC9;
Lightblue), and RBD4 (PDB ID: 2FC8; deep olive). RMSD scores for RBD1, RBD2, RBD3, and RBD4 are 3.594,
2.324, 1.775, and 2.442 angstroms, respectively. B. Superposition of the modeled RBD3-4 (pale green)
with individual structures of NCL RBD3 (PDB ID: 2FC9; Lightblue), and RBD4 (PDB ID: 2FC8; deep olive)
RMSD scores for RBD3 and RBD4 are 0.956 and 1.753 angstroms, respectively.

Structural information of miRNA molecules is largely unavailable in the current databases.
Therefore, 3D miRNA models generated based on secondary structure prediction using 3D
modeling programs were evaluated to identify top ranked models (Figure 12). Additionally, if
multiple models were ranked the same in structural evaluation profiles (Table 5), they were all
used in RNA-Protein docking analysis to check for reproducibility of results. Our predicted models
provide a complete picture of the structural information for both NCL and the miRNA analyzed
in this study.
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Figure 12. Structural models of the miRNAs analyzed in this study. Top ranked models for all 6 pri-miRNA
(orange backbone with bases shown in blue). Alternative miRNA models that exhibited comparative
evaluation profiles are shown in dark red.

Docking analysis of miRNA with NCL-RBDs reveals 3 possible NCL-RBD-miRNA interaction
scenarios
Based on our comprehensive analyses of NCL-RBDs and a set of NCL-interacting miRNAs we
suggest 3 possible binding modes between NCL-RBDs and miRNA molecules:
Mode 1: Both RBD3 and RBD4 form the RNA-protein interaction interface
This binding mode consists of RBD3, RBD4 and the linker region between RBD3 and RBD4. In this
binding mode, RBD3 contributes with its conserved basic and aromatic residues within the RNP1
motif (K533, Y535, F537). Charged residues on the β-4 strand (R564, E566) were also identified
as part of this binding mode. RBD4 on the other hand doesn’t contribute with its RNP motifs, but
rather with Arg residues on its β-2 strand (R607, R609) and the linker region between β-2 and β-
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3 (R614). The linker region between RBD3 and RBD4 contributes with mostly polar or charged
residues (R571, R577, Q569) In this putative binding mode, RBD3 and RBD4 interact with the
double stranded RNA from opposite ends and cooperate to hold the miRNA molecule in a clasped
orientation where additional interactions conducted by the linker region between RBD3 and
RBD4 further strengthens this binding event (Figure 13). This binding mode is predicted for the
interactions of mir-16, mir-221, and mir-222 with NCL.

39

40

Figure 13. Representative docking poses exhibiting binding mode 1 involving RBD34. A. Complete
docking scenarios. B. Zoomed-in version that focuses on the RNA-protein interaction interface. miRNA
molecule backbone (orange), RBD1 (marine blue), RBD2 (deep salmon), RBD3 (light blue), RBD4 (deep
olive), and linker regions between RBDs 1-2 and 3-4(neon green) and 2-3 (yellow). Interacting nucleotides
on the miRNA and NCL-RBDs are indicated with deep teal and hot pink, respectively.

Mode 2: RBD4 forms the major component of the interaction interface
This binding mode 2 features RBD4 and the linker region between RBD3 and RBD4. Again,
anticipated basic and aromatic residues on the RNP1 motif (K620, F622, F624) and the RNP2
motif (F585) were identified as the major component of the interaction interface. Additionally,
Arg residues previously identified in mode 1 on β-2 strand (R607, R609) and on the linker loop
between β-2 and β-3 (R614) were frequently identified in forming hydrogen bonds and salt
bridges. The only residue identified as part of this binding mode from the linker region between
RBD3 and RBD4 is S578. In summary, this binding mode is exclusively comprised of RBD4. It also
bears resemblance to the mir-18 binding mode of HNRNP A1 [26], both in terms of the
composition and location of the residues involved in the interaction and in the overall
arrangement of the beta strands. In both cases, the interactions are driven by residues on 3
beta strands of the same RBD. This binding mode is predicted in the mir-15a and mir-103
docking scenarios (Figure 14)
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Figure 14. Representative docking poses exhibiting binding mode 2 involving RBD4. A. Complete
docking scenarios. B. Zoomed in version that focuses on the RNA-protein interaction interface RBD1
(marine blue), RBD2 (deep salmon), RBD3 (light blue), RBD4 (deep olive), and linker regions between RBDs
1-2 and 3-4(neon green) and 2-3 (yellow). Interacting nucleotides on the miRNA and NCL-RBDs are
indicated with deep teal and hot pink, respectively.

Mode 3: RBD3-4 predominantly drive the interactions with a minor contribution of RBD1-2
In this mode 3, RBD3 and RBD4 again make up the predominant part of this binding mode. RBD1
and RBD2 were predicted to make minor contributions, too. In this binding mode RBD3
contributes with aromatic and basic residues within the RNP1 motif (K533, Y535, F537) and the
newly identified polar residues on its β-4 strand (R564, E566). RBD4 on the other hand
contributes with its Arg residues on its β-2 strand (R607, R609). These residues were also
42

identified in binding mode 1. Besides the involvement of both RBD3 and RBD4 just as it was
predicted in binding mode 1, RBD1-2 is predicted to have a minor contribution in binding mode
3. K439 was the most frequently predicted residue from RBD2. This binding mode (Figure 15) is
only predicted with mir-21 docking scenarios.

Figure 15. Representative docking poses exhibiting binding mode 3 involving RBD234. A. Complete
docking scenarios. B. Zoomed in version that focuses on the RNA-protein interaction interface. RBD1
(marine blue), RBD2 (deep salmon), RBD3 (light blue), RBD4 (deep olive), and linker regions between RBDs
1-2 and 3-4(neon green) and 2-3 (yellow). Interacting nucleotides on the miRNA and NCL-RBDs are
indicated with deep teal and hot pink, respectively.

RNP motifs are conserved on all 4 NCL-RBDs but RBD-miRNA interactions are driven primarily
by RBD 3 and 4
An alignment of NCL-RBDs with the HNRNP A1 shows the conservation of the RNP motifs as well
as the key residues that are involved in HNRNP A1-RNA/DNA interactions in all 4 NCL-RBDs
(Figure 16A). However, our docking studies predict the RNP motifs of RBD3-4 are predominantly
involved in miRNA interactions (see docking results, Figures 13-15). The aromatic and basic
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residues within RNP1 (K533, Y535, F537) of RBD3, RNP1 (K620, F622, F624) and RNP2 (F585) of
RBD4 were very frequently predicted NCL residues at the RNA-protein interface, as expected
from the literature (Figure 16B). Apart from the anticipated residues, a few Arg residues on RBD4
(R607, R609, and R614) were also very frequently predicted.

Additionally, the linker region

connecting RBD3 to RBD4 contains several residues frequently predicted to be involved in NCLmiRNA interactions (R571, N575, R577, Q579; not shown in the figure).

Figure 16. NCL residues predicted to interact with miRNAs A. Comparison of HNRNP A1 RBDs with NCLRBDs (PDB ID: 6DCL). Beta strands and RNP motifs are indicated with arrows. Known HNRNP A1 residues
that interact with ssDNA and miR-18 are indicated in light brown background. NCL residues conserved in
the equivalent positions are indicated in yellow background. Conserved residues are indicated in bold and
black background. B. Summary of NCL-RBD residues most frequently predicted to interact with miRNA
based on docking. Different types of interactions are indicated with background colors C. Summary of
predicted NCL-miRNA binding modes and a comparison with HNRNP A1-miRNA binding model. 1.
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Known HNRNP A1-mir18 interaction residues. 2. Proposed NCL-miRNA binding mode 1 where both
RBD3&RBD4 are involved in the interactions. 3. Proposed NCL-miRNA binding mode 2 where RBD4 alone
interacts with miRNA 4. Proposed NCL-miRNA binding mode 3 which in RBD3&4 and a single residue from
RBD2. Beta sheets are numbered on top, and residues predicted to interact with miRNA are indicated in
red. Newly identified residues are indicated in black. The numbers indicate the position of these residues
in the corresponding beta strands. RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582-656

These results are corroborated by a predictive analysis based solely on primary structure using
the Catrapid algorithm that similarly suggests RBD3, RBD4, and the linker region between RBD34 have the highest RNA binding propensity for all tested miRNA molecules (Figure 17).

Figure 17. CatRAPID results of NCL RBD1-4 for all miRNA sequences used in this study. Red regions
indicate a strong indicator for RNA binding propensity (the taller the red peaks, the greater the
propensity). RBD1: 1-77 RBD2: 87-160 RBD3: 180-254 RBD4: 266-340
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Additional control docking experiments of NCL RBD1-4 with miR-155, a microRNA reported to be
not affected by NCL exhibited noisy and inconsistent results with no clear selectivity for any
particular RBD (Figure 18), supporting the robustness of our in-silico predictions.
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Figure 18. Inconsistent interactions displayed by RBD1-4-mir155 docking results. RBD1 (marine blue),
RBD2 (deep salmon), RBD3 (light blue), RBD4 (deep olive), and miRNA (orange), linker region connecting
RBDs (neon green)

Aromatic and basic residues play a key role at the NCL RBD3-4-miRNA interface
RNA-NCL docking scenarios of both RBD3-4 and RBD1-4 with miRNA models highlight the role of
some of the positively charged arginine residues in β-2 (R607, R609) as well as the linker between
β-2 and β-3 on RBD4 (R614) as these residues are consistently predicted to be involved in nearly
all the docking scenarios analyzed. These basic residues form salt bridges with the phosphate
backbone of the various miRNAs. Similarly, our results indicate that aromatic residues on β-1
(F585 in RBD4) and β-3 (Y535 and F537 in RBD3 & F622 and F624 in RBD4) interact with miRNA
molecules through π-π stacking and π-anion interactions with the nucleobases and the
phosphate backbone, respectively. Importantly, the docking analysis of RBD1-4 models align
with those of RBD3-4 models (Figure 19). Our results also show that residues on RNP motifs from
RBD1-2 are largely not involved in NCL RBD-miRNA interactions, despite the similar functional
profile of the RNP motifs. A control docking analysis using only RBD1-2 yields noisy scenarios with
no clear trend, again reinforcing the idea that NCL RBD3-4 preferentially interact with the miRNA
under study.
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Figure 19. MSA map of RBD3 and RBD4 predicted to be involved in NCL-miRNA interactions. The types
of interactions are color coded as indicated at the bottom. Residues with similar composition at the
same position are indicated in red boxes. RBD3: 496-570, RBD4:582-656

Based on the docking results, we show that NCL-RBDs interact with pri-miRNA nucleotides
almost exclusively within the region that corressponds to the mature miRNA molecule. In our
results, NCL is predicted to interact frequently with G-U pairs and kink turns (Figure 20).
Interactions were observed predominantly at the major groove regions of the double stranded
miRNA molecules as these regions were more accessible when compared to the minor groove
regions.
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Figure 20. Location of non-canonical base pairing nucleotides and motifs in miRNA that interact with
NCL-RBDs. miRNA residues most frequently predicted to interact with NCL-RBDs are show in cyan for all
miRNA structures where pri-miRNA is shown in orange and region of the mature miRNA is shown in red.
Non-canonical base pairs and kink-turns are indicated in dark purple.
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Discussion
NCL RBD3-4 utilize aromatic and basic amino acid enriched RNP motifs to recognize miRNAs,
similar to the miRNA binding protein, HNRNP A1
The importance and functionality of RNP motifs in RBP-RNA interactions are well established in
previous studies [23]. Since there is a high sequence similarity between NCL and HNRNP A1 RBDs,
and HNRNP A1-RNA interactions are known, an initial and preliminary prediction of putative
residues that may be important in NCL-miRNA interactions could be made based on sequence
conservation between NCL and HNRNP A1. The RBP-HNRNP A1 interacts with MPC and pri-mir18 by utilizing aromatic/charged residues found on its RNP motifs as well as on non-RNP beta
strands [10]. These aromatic/charged residues show strong conservation between NCL and
HNRNP A1 sequences suggesting existence of a similar RNP-mediated mechanism in NCL-miRNA
interactions (Figure 16A). This study confirms such predictions through detailed docking analyses
in silico. Our results provide three alternative NCL-miRNA binding possibilities with common
underlying conserved residues at an equivalent position as in HNRNP A1-RBD taking part in RNA
binding (Figure 16C). Aromatic residues in the RNP motifs are known to be capable of initiating
interactions with multiple nucleobases at the same time through π-π stacking interactions and
promoting structural stability to the RNA-RRM motif binding [23]. We consistently predicted the
involvement of these aromatic residues in all binding modes of miRNA-NCL. Additionally, we
frequently predicted some charged residues on different beta strands from the same RBDs to be
involved in NCL-miRNA interactions. Several arginine residues (R607, R609, and R614) were
consistently predicted to interact with phosphate groups on the nucleotides via salt bridges (e.g.,
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R609 in Figure 13 with G16, A34, and U45 in figures for mir-16, mir-221, and mir-222,
respectively). These residues provide additional structural stability to RNA-protein interactions
similar to previous studies [26]. Our docking results also revealed that each NCL-RBD interacts
with the miRNA duplex structure from opposite sides and forms a clasp around it. Linker regions
between RBD3 and RBD4 were consistently predicted in several scenarios to hold the miRNA
molecule from an additional third side, thus tightening the NCL-RBDs grip on miRNA (Figures
13,15).
NCL RBDs are predicted to interact with UGU/GUG motifs on pri-miRNA molecules
Our results indicate that NCL-RBDs demonstrate preference or affinity for interaction with certain
types of miRNA motifs. It was previously established that NCL prefers interacting with RNA loops
while driving ribosomal biogenesis [121]. Non-canonical base pairing is known to lead to kinkturns, bulges, mismatched pairs, and wobble pairs in miRNA structures and presents suitable
interaction sites that would be unavailable otherwise. In canonical pairs such as G-C or A-U,
amino groups of each base-pair are projected into the major groove, creating a region with
positive electrostatic potential [122]. The G-U base-pair is an example of non-canonical base pair,
where oxygen groups from both nucleotides face the major groove side instead of the amino
groups and leading to negative electrostatic potential in the region of the major groove of the
dsRNA [123]. Our results also highlighted the preference of NCL RBDs on non-canonical base pairs
when interacting with miRNAs (Figure 20). Such regions are expected to interact with amino acids
with positively charged side groups such as arginine or lysine [122]. This ties in with our results
as several arginine and lysine residues from NCL RBD3-4 were predicted as some of the most
frequently encountered residues in the various docking scenarios obtained.
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Additionally, wobble pairs and mismatched pairs are known to be important elements of primary
miRNA processing by the MPC [124]. Certain RNA motifs such as UGU/GUG are known to be
enriched around the apical loop regions [124] and the preference of NCL to interact with regions
close to the apical loops has been demonstrated in previous studies investigating NCL-rRNA [121]
and NCL-mRNA [19] interactions. This consensus sequence is also important in pri-miRNA
processing by the MPC as DGCR8 is thought to recognize and interact with this consensus
sequence [125]. Our results revealed that NCL RBDs were able to recognize this UGU/GUG motif
for all miRNA molecules tested in this study (Figure 21). In the cases of mir-15a and mir-103,
these regions were identified adjacent to apical loop structures. It is also interesting to note that,
in binding mode 2 (observed in mir15a and mir103a), RBD4 by itself seems sufficient to drive
NCL-miRNA interactions (Figure 21A). In the cases of mir-21 and mir-16-1, NCL interacts with
regions distant from apical loops, but closer to bulge regions towards the middle of the miRNA
molecule. (Figure 21B). Since DGCR8 also recognizes the same motif for interactions, our results
suggest that NCL potentially binds adjacent to DGCR8 or could even replace it in as a possible
scenario of miRNA – NCL interactions. Alternatively, in the cases of mir-221 and mir-222, NCLmiRNA interactions were predicted to be localized slightly distant to the apical loop region and
closer to the basal stem region containing a mismatched GHG/CUC motif (Figure 21C). This
manifests as a mismatched bulge, which is a common element in most pri-miRNA structures
[124]. Drosha cleaves its miRNA targets around the basal stem close to this motif [125]. This
cooperation model suggests that NCL-RBDs binds closer to Drosha. In both scenarios, these
motifs likely serve as anchoring points for NCL-RBDs when they interact with miRNA in
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cooperation

with

MPC.

Figure 21. Mapping of miRNA residues interacting with NCL. A. NCL contacts miRNA molecules at the
UGU/GUG motifs closest to the loop. B. NCL contacts miRNA molecules on UGU/GUG motifs distant from
the loop and closer to GHG/CUC motifs. C. NCL contacts longer miRNA molecules on UGU/GUG motifs
slightly distant from the apical loop and closer to the loop stem. Beta strands are numbered on top of the
arrowheads. RBD1 (marine blue), RBD2 (deep salmon), RBD3 (light blue), RBD4 (deep olive), and linker
loops between RBDs (neon green). UGU/GUG motifs on miRNA that NCL interacts are indicated in green.
miRNA residues that NCL interacts with are but is not part of an UGG/GUG motif is indicated in purple.
UGU/GUG motifs on miRNA that NCL is not interacting are indicated in red. GHG/CUC motifs are indicated
in orange.

Similarly, many other RBPs including HNRNP A1, Lin28B, RBFOX3, and HuR interact with either
the terminal loop or the stem regions of the pri-miRNA molecules to either promote or suppress
pri-miRNA processing by the MPC proteins depending on the location of the interactions and the
targeted miRNA. For example, both Lin28B and HNRNP A1 interact with the terminal loop of a
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subset of pri-miRNA structures. HNRNP A1 is predicted to help with the processing of pri-miR18a by binding to the terminal loop and causing a relaxation of the miRNA structure and therefore
making it easier for MPC to interact with miRNA [126]. However, when HNRNP A1 interacts with
let-7 pri-miRNA terminal loop, it outcompetes binding of another RBP, KH-type slicing regulatory
protein (KSRP) known to promote biogenesis of let-7 [127] and decreases pri-miRNA processing
by Drosha. Lin28B, on the other hand, always negatively regulates this process by interacting
with the terminal loop and inhibiting Drosha from interacting with miRNA [128]. Both RBFOX3
and HuR bind to the basal stem and inhibit miRNA processing by blocking catalytic activity of
Drosha [129,130]. Based on these studies, it is clear that the relationship of RBPs with the MPC
is both location and context dependent.
NCL may cooperate with or replace DGCR8 as a dsRBP in pri-miRNA processing of different
types of miRNAs
A recent structural study investigating interactions of the MPC with pri-miR16-2 revealed that 2
DGCR8 proteins interact with nucleotides adjacent to the apical loop region of the pri-miRNA
molecule [131]. The canonical function of DGCR8 is to interact with pri-miRNA using its double
stranded RNA binding domains (dsRBDs) and present the pri-miRNA molecules to Drosha for the
first processing step of miRNA molecules [96]. This is illustrated in Figure 23A. Many RBPs can
interact with regions of pri-miRNA molecules where DGCR8 proteins bind. We speculate that
NCL-RBDs promotes pri-miRNA processing of certain miRNAs by a similar mechanism as observed
in HNRNP A1-mir18 interactions. As an RBP capable of binding double stranded RNA molecules,
NCL could potentially replace the pri-miRNA presenting functions of one or both DGCR8 proteins.
Our results suggest that for certain miRNA, NCL can wrap around the double stranded miRNA
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molecule with two RBDs like DGCR8 (Figure 22B). Since the lengths of oncogenic miRNA
transcripts are variable, we speculate that NCL may act as a bridging agent between DGCR8 and
Drosha when processing longer transcripts (Figure 22C). Our findings present a snapshot of NCLmiRNA that give an initial insight into these interactions. We envision future studies to elaborate
the NCL-miRNA interaction dynamics over longer time-scales to get a finer grained picture of the
molecular mechanisms underlying these mechanisms and their downstream effects.

Figure 22. Canonical and proposed models of NCL, Drosha, and DGCR8 interactions with pri-miRNA
molecules. A. Canonical model involving Drosha & DGCR8 -1and 2[130] B. Hypothetical model A where
NCL-RBDs could replace DGCR8 – 2 C. Hypothetical model B where all MPC proteins and either one or
both NCL-RBDs interact with the pri-miRNA molecule. NCL-RBD3&4 are colored in light blue and deep
olive, respectively. DROSHA is light green. DGCR8-1 is red, and DGCR8-2 is orange.
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Chapter 3: Investigation of NCL – mRNA interactions
The human genome contains approximately 30000 genes and on an average every gene gets
alternatively spliced and translated to yield 3 unique protein isoforms or alternate splice variants
[132]. However, this process is heavily regulated at every step. NCL, being an RBP, is intricately
involved in the regulation mechanisms at the level of processing of the transcript or RNA. One
mechanism through which NCL accomplishes this is through its interactions with the untranslated
regions (UTRs) of mRNA transcripts, which are prime targets for NCL to implement its regulatory
effects. Further, studies have shown that some of these interactions of NCL with its mRNA targets
are associated with enhanced tumorigenesis [29].

However, the molecular mechanisms

underlying the NCL mediated regulation of mRNA is completely unknown primarily due to the
absence of structural information for the mRNA molecules and the partial nature of structural
information of the NCL RBDs as explained in Chapter 1. In this chapter, we present our attempts
to elucidate the molecular mechanisms driving NCL-mRNA UTR interactions in a select set of
cancer related mRNA UTRs using in silico tools.
Gene expression regulation mediated through interactions with mRNA untranslated regions
The central dogma dictates the typical flow of genetic information from DNA to RNA to protein
and the information relayed along this flow is subject to numerous regulatory mechanisms that
determine the final expression levels of genes within a cell [133]. These regulatory processes are
accomplished via various distinct mechanisms at multiple levels to finely calibrate requisite gene
expression, especially at the mRNA level. Both non-coding RNA molecules and RBPs are capable
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of interacting with both coding regions and untranslated regions of mRNA molecules posttranscriptionally [134].
Regulation of expression levels of a gene via the 3’ and 5’ untranslated regions is one potential
route by the molecular machinery to alter the expression levels of the transcribed mRNA [135].
After being transcribed from the corresponding genes into mRNA by RNA Polymerase II, a 5’
methyl guanosine cap and a 3’ poly A-tail is added to both sides of the transcript [136] to serve
as tags for differentiating the coding region from the untranslated region of an mRNA sequence.
Although untranslated regions of an mRNA molecule are themselves not translated by the
ribosomes, they contain sequence/structural elements that influence the rate and level of
translation of that transcript [137]. Both RBPs and miRNA recognize these structural/sequence
motifs thereby allowing them to bind to and interact with these regions [137]
Originally only miRNA molecules were thought to interact with compatible single stranded
sequences on the coding region of the transcript and creating a transient double stranded region.
This double stranded structure blocks the translation process by a ‘physical obstruction’
mechanism, preventing the sliding ribosome to move along the single stranded RNA. This stalling
of the translation process leads to increased rates of deadenylation on the poly A-tail side and
thereby inducing RNA decay [138]. In a similar manner, the 5’ UTR is known to contain internal
ribosome entry sites and formation of mRNA-protein complexes in the 5’ UTR attenuates
translation rates by inducing a steric blockage to the translation initiation process [139].
Therefore, it is likely that biomolecules with high binding affinity to specific sequence/structural
motifs on certain mRNA regions can obstruct the path of the traveling ribosomes. Additionally,
3’ UTR contain binding sites for both proteins and miRNA molecules and interactions at these
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regions impact polyadenylation, localization, and stability of the mRNA molecule [140]. RBPs can
either recruit other proteins to promote deadenylation and mRNA decay further or alternatively
they can occupy certain regions on 3’ UTR to reduce deadenylation rates [141].
A previous study has demonstrated that mature miRNA molecules bound to their target
sequence and the RNA-induced silencing complex (RISC) proteins, dicer, argonaute and TRBP
were found to be accumulating in P-bodies [142]. P-bodies are believed to hold translationally
repressed mRNA molecules along with compatible miRNA molecules and other RBPs that
accompany them [142]. Since various RBPs accompany these RNA molecules to their final
destination, it is conceivable that some of these RBPs might orchestrate these processes through
their interactions with both the RNA and other regulatory proteins.
RBPs are known to interact with all possible regions on an mRNA transcript, including the 3’ UTR,
the coding region, 5’ UTR and the poly-A tail. These interactions can both drive promotion and
suppression of translation in multiple ways. For example, poly-A binding protein B(PABPB) is an
RBP that protects mRNA scripts from deadenylation and therefore preventing mRNA decay [143].
Poly-A binding protein C1 (PABPC1) on the other hand may induce mRNA decay by recruiting
polyadenylase proteins to the 3’ poly-A tail of an mRNA transcript [143]. Surprisingly, depending
on the cellular conditions, PABPC is known to promote activation of translation by interacting
with certain mRNA, eukaryotic translation initiation factor 4G (eIF4G), and other RBPs and
promoting structural stability to the closed-loop formation for an efficient translation of the
transcript [144]. The dualistic nature of these RBP functions in regulating gene expression is
reflected by the paradoxical roles they can undertake.
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NCL-mRNA interactions in human cancers
NCL has been reported to interact with the untranslated regions of many mRNA molecules. For
this study, we selected to investigate a subset of mRNA UTRs including TP53 [19], IL-2 [145], BCL2 [43], and CSF1 [18] because of their key role in cellular processes such as DNA damage repair,
apoptosis, proliferation, and metastasis. Dysregulation of these cellular processes are known
hallmarks of tumorigenesis [146].
TP53 encodes for a well-known tumor suppressor protein, p53. It is capable of activating the DNA
damage response pathway, and deciding whether apoptosis is triggered or not, ultimately
deciding the fate of the cell. p53 is essential for maintaining stability of the genome and it is not
surprising that in almost half of all cancers, the TP53 gene is mutated [147]. Aptly termed
‘guardian of the genome’, p53 is tightly regulated with respect to the stress levels of the cell. The
successful localization of p53 mRNA into polysomes is dependent on the interaction of its UTR
with ribosomal protein L26 (RPL26) [19]. Under DNA damage conditions, NCL is an active
component of the regulation of p53 translation. A competitive inhibition sets in as the promotion
of translation of the p53 mRNA by RPL26 is suppressed by the interactions of NCL with RPL26.
The basis for this competition lies in the details of the interaction interface of the proteins with
the mRNA UTRs; NCL interacts with both the 3’ and 5’ untranslated regions of p53 where some
of the sequence motifs recognized by RPL26 also reside [19]. Therefore, when NCL is
overexpressed, it results in suppression of p53 mRNA expression, which in turn leads to stalling
of DNA damage repair processes and apoptosis [19].
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NCL interacts with the 5’ UTR of B cell Lymphoma 2 (bcl2) mRNA and this interaction results in
stabilization of the transcript by protecting it from deadenylation [43]. Bcl2 is an important
regulator of apoptosis, and its anti-apoptotic properties can effectively block programmed cell
death. Therefore, Bcl2 is considered an oncogene [148]. Since NCL promotes Bcl2 translation
rates, NCL overexpression can lead to increased translation rates of Bcl2 and the cellular balance
can shift to an increased tendency to avoid apoptosis, resulting in promotion of tumorigenesis.
NCL is known to interact with multiple regions in 3’ UTR of Colony stimulating factor 1 (CSF1) and
promotes mRNA decay when overexpressed in ovarian cancer cells [18]. mRNA decay was
observed to involve two miRNA molecules (mir-130a and mir-301a) that have complementary
regions to the CSF1 mRNA 3’ UTR. This miRNA directed process is dependent on NCL. When NCL
was silenced in ovarian cancer cells overexpressing these miRNA molecules, this miRNA
dependent mRNA decay was abolished. Interestingly, NCL overexpression also paradoxically
resulted in increased CSF1 protein levels even when steady state mRNA levels decreased.
Interestingly, overexpression of only the NCL RBDs resulted in greatly increased steady state
mRNA levels and moderately increased protein levels. CSF1 is known to promote proliferation
[148] and overexpression of NCL could lead to increased CSF1 protein levels and therefore
promote tumorigenesis through uncontrolled proliferation.
NCL interacts with the 5’ UTR of Interleukin factor 2 (IL2) mRNA and stabilizes the transcript [145].
IL-2 is a critical cytokine in maintenance and differentiation of T-cells, and it is a well-established
target in immunotherapies. NCL is thought to stabilize IL2 mRNA through interactions with both
the mRNA and proteins from the c-Jun N-terminal kinase (JNK) pathway, involved in regulation
of signaling from different sources of stress [150]. In tumor cells, a decrease in IL-2 results in an
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increase of cyclin dependent kinase inhibitor proteins p21 and p27 which are involved in cell cycle
progression between G1 and S phase and G0 and S phase, respectively [151]. P21 is an important
protein that is responsible for cell cycle arrest and depending on the context and location it can
act as a tumor suppressor or an oncogene [152]. P27 is also considered as a tumor suppressor
and is often inactivated in human cancers [153]. Since NCL stabilizes IL2 mRNA and IL2
suppresses p21 and p27, overexpression of NCL can potentially result in stabilization of IL2 mRNA
and increasing IL2 protein levels. Increased IL2 levels are expected to drive attenuation of p21
and p27 protein levels, which would in turn lead to bypassing cell cycle checkpoints, and
therefore linking it to tumorigenesis.
In summary, NCL interacts with mRNA UTR molecules of important genes involved in cellular
processes linked to tumorigenesis. Overexpression of NCL in a human cancer background
suppresses tumor suppressors, promotes translation of oncogenes, often leading to bypass of
programmed cell death as well as DNA damage repair mechanisms, and cell cycle checkpoints
through interactions with mRNA UTR sequences. The nature of interactions between NCL and
mRNA UTR sequences investigated in this study and the outcomes of these interactions with
respect to tumorigenesis are summarized in Table 6 below.
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Table 6. Summary of NCL-mRNA UTR interactions investigated in this study

Gene name

Canonical functions

Downstream effects
of interaction with
NCL
Translation
suppression

Observed
tumorigenic
phenotype
Avoiding DNA damage
response &apoptosis

TP53

Tumor suppressor

Bcl2

Apoptosis regulator

mRNA stabilization

Avoiding apoptosis

IL2

Regulates activities of
white blood cells

mRNA stabilization

Avoiding apoptosis

CSF1

Promotes
proliferation

mRNA stabilization

Increased
proliferation

Known regions/motifs of mRNA UTRs and RBD specificity in the interaction of NCL -mRNA UTRs
Although the detailed mechanism of the interactions we are investigating is not known at the
molecular level, some important details and clues are available from previous studies and are
summarized in Table 7 and explained below.
•

NCL interacts with 2 regions on CSF1 3’ mRNA UTR. The shorter region (CSF1s) contains 49
nucleotides(nts), and the longer region (CSF1l) contains 162 nts. RBD1-4 was found to be
capable of driving these interactions [18]. CSF1s contains 6 potential G-quadruplex structures
(GGG) and NCL is known to interact with these motifs.

•

NCL interacts with both the first 355 nts on 3’ UTR (P53l) and the last 75 nts of 5’ UTR (P53s)
of TP53 mRNA. Although it is very long, the first 355 nts of TP53 3’ UTR contains AU-rich
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sequences that could potentially serve as recognition motifs for NCL. RBD1-4 is sufficient to
drive this interaction although it is interesting to note that the N-terminus+RBD1-2 construct
doesn’t interact with this region [19]. The last 75 nts of TP53 5’ mRNA UTR (P53s) are believed
to contain apical loop and hairpin loop structures which could serve as potential anchoring
points for NCL. The N-terminus+RBD1-2 can interact with this region, although with a
decreased affinity when compared to RBD1-4 [19].
•

NCL interacts with a 91 nt region found in 3’ UTR of Bcl2 mRNA. This is a G-rich sequence and
NCL is known to have affinity for the G residues in this region. In addition, a AUUUA pentamer
and an 11mer AUUAUUUAUUU are potential motifs that NCL interacts with. Experiments
show that RBD1-4 has the greatest affinity for this region and RBDs 1 and 2 display a similar
affinity. However, RBDs 3 and4 have an approximately 5 times lower affinity for this mRNA
UTR [43]. Therefore, it is deduced that RBDs 1 and 2 play a greater role in the interaction.

•

NCL interacts with a 57 nt region found in 5’ UTR of IL2 mRNA. This region was thoroughly
tested in a study and results revealed that NCL preferentially binds to nucleotides between
positions 3-22 [145]. The rest of the sequence was deemed not to be critical. RBD1-4 was
found to be capable of driving these interactions.

Table 7. Summary of RNA motifs and NCL domains known to interact with.
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Dysregulation of these mechanisms are known hallmarks of human cancers but molecular
mechanisms driving these tumorigenic activities have not been investigated in any previous
study. Identification and verification of these interactions would provide critical information in
identification of druggable targets from a therapeutical perspective. Therefore, elucidation of
molecular mechanisms driving these interactions is critical in gaining a better understanding on
how to address these complex interactions. Unfortunately, crystal structures for both NCL RBD14 and mRNA UTR regions are currently unavailable in the structural databases, without which it
is not possible to uncover the detailed molecular mechanisms of these interactions. This chapter
aims to approach this gap of information by using computational tools and generating 3D models
of protein and RNA molecules so that RNA-protein docking algorithms can reveal predictive
scenarios with details of the interaction interface.
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Methods
A flowchart summarizing the general protocol of the present study with the various tools used to
analyze NCL-miRNA interactions (discussed in detail later) is shown below.

Figure 23. Flowchart depicting the methods and tools utilized in this chapter. Individual steps and
programs/algorithms utilized in those steps are indicated in blue and white boxes, respectively

Sequence analysis and generation of 3D models of NCL-RBDs
NCL RBD1-4 models generated as described in the previous chapter were used in these
experiments. For detailed information about individual steps in NCL RBD modeling, please refer
to the methodology section in Chapter 2
Generation of 3D models of mRNA UTR molecules implicated in interactions with NCL
Since only the primary sequences of the mRNA UTRs analyzed in the current study are known
(Table 8), generation of the three-dimensional models of mRNA UTR molecules was
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accomplished by the same protocol in the previous chapter except the SSP algorithm MC-SYM
was replaced with another program, Vfold5 [154] as MC-SYM was unavailable for use due to
technical issues. Evaluation and refinement of models were conducted using the same methods
and tools as in the previous chapter. The top 3 3D models were used in the docking analysis.
Table 8. Summary of mRNA UTR molecules investigated in this study. Accession numbers are listed
below the name of the UTR.

Prediction of motifs involved in NCL-mRNA interactions
The interactions scenarios were generated using HDOCK [115] and the analysis was conducted
using the same methods and tools as in the previous chapter. The most frequently predicted
residues were ranked, and top 15 residues were identified in both the RNA and protein
molecules. The final investigation was focused on identification of trends, where a list of residues
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was consistently predicted in multiple scenarios and/or multiple models. Any interactions
verified by experimental means from previous studies was utilized as guiding principles in
establishing a baseline for comparison with predicted results. Additional information regarding
RNA motifs that NCL might recognize when targeting an RNA molecule was utilized to guide our
predictions e.g., well-established NCL recognition elements such as AU rich regions [43,59], Grich regions [60,61], and apical loop structures [16,61] were prioritized in the analysis. In silico
control experiments were conducted to compare the p53 3’ UTR binding capabilities of NCL and
RPL26. The representative 3D model of RPL26 was obtained from Alphafold database. Alphafold
database is a public database for protein structure predictions executed by the Alphafold
algorithm (155).
Results
Preliminary mapping of known regions/motifs of mRNA UTRs involved in interaction with NCL
As outlined in the introduction, prior studies investigating NCL-mRNA UTR interactions provide
critical structural information that is important for incorporation in the generation of the 3D
structures of RNA molecules and evaluating docking scenarios. NCL is known to have an affinity
for certain motifs such as AU rich regions and G rich sequences [43,59,60,61]. Additional studies
also point to recognition of some NCL targets by apical loops as well [16,61]. These regions and
motifs were taken into consideration when selecting the regions to be modeled as well as
analyzing the modeling/docking results and are summarized in Table 9 below. This preliminary
mapping of NCL preferred motifs in different NCL-mRNA UTR interactions served as a guide to
analyze and discriminate valid RNA-docking scenarios (described later).
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Table 9. Nucleotide sequences of NCL interacting UTR regions of mRNAs investigated in this study.
Experimentally verified residues are indicated in red, predicted residues are indicated in purple.

Structural models of specific mRNA UTRs provide a complete structural picture needed to study
NCL-mRNA interactions
A. Secondary structure prediction of mRNA UTR molecules that interact with NCL
Using the primary sequence of NCL interacting mRNA UTR molecules involved in cancer, as
identified in previous studies, we performed a comprehensive secondary structure analysis of
these sequences detailed below.
1. CSF1 mRNA 3’ UTR (2921-2970) (CSF1s)
As the shortest molecule investigated (49nt), CSF1s predictions generated by different algorithms
displayed certain elements to be in common in majority of the results although there were minor
differences as well. All models had one apical loop structure with the same sequence and
orientation as indicated in blue circles in Figure 24. The main difference between the predictions
is observed in the big multiloop structure.
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Figure 24. Secondary structure predictions for CSF1s. Dot bracket structure of predictions are indicated
below every figure. Common RNA motifs are indicated in blue circles. A. Centroidfold B. RNAFoldMFE C.
RNAFoldCentroid D. RNAStructure E. SPOTRNA

2. IL-2 mRNA 5’ UTR (239-296) (IL2)
As the second shortest molecule investigated (57nt), IL-2 mRNA predictions generated by
different algorithms were compared, and only SPOTRNA predicted a small pseudoknot
connecting the last 3 nucleotides with the first 3 nucleotides of the sequence. Although all
predictions were different, an apical loop was common to all structures. These apical loops are
indicated in colored circles in Figure 25
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Figure 25. Secondary structure predictions for IL2. Dot bracket structure of predictions are indicated
below every figure. Common RNA motifs are indicated in blue circles. Unique RNA motifs are indicated in
green, purple and yellow circles. A. Centroidfold B. RNAFoldMFE C. RNAFoldCentroid D. RNAStructure E.
SPOTRNA

3. p53 mRNA 5’ UTR (68-144) (p53s)
As the shorter molecule investigated in the middle group based on size (75nt), p53s predictions
generated by different algorithms varied to a high extent. RNAFoldMFE and RNAFoldCentroid
algorithms predicted the same secondary structure. Although 2 apical loop structures on both
ends of the molecule were predicted by most algorithms, as indicated by blue circles in Figure
26, the location and the size of these structures had minor differences. SPOTRNA predicts a
pseudoknot connecting the first 5 nucleotides to the region adjacent to the apical loop that starts
at position 50, as indicated by green lines in Figure 26.
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Figure 26. Secondary structure predictions for P53s. Dot bracket structure of predictions are indicated
below every figure. Common RNA motifs are indicated in blue circles. Green lines indicate pseudoknot
interactions. A. Centroidfold B. RNAFoldMFE/RNAFoldCentroid C. RNAStructure D. SPOTRNA

4. BCL2 mRNA 3’ UTR (1772-1863) (BCL2)
As the longer member of the middle group (91nt), BCL2 mRNA also displays a greater degree of
variation in predictions. All algorithms except SPOTRNA predicted 2 apical loops on both ends of
the molecule, as indicated by blue and purple circles in Figure 27
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Figure 27. Secondary structure predictions for BCL2. Dot bracket structure of predictions are indicated
below every figure. Common RNA motifs are indicated in purple and blue circles. A. Centroidfold B.
RNAFoldMFE C. RNAFoldCentroid D. RNAStructure E. SPOTRNA

5. CSF1 mRNA 3’ UTR (3698-3860) (CSF1l)
CSF1l is the longer sequence of the CSF1 mRNA 3’ UTR region that NCL interacts with (175nt) and
is the second longest sequence in the list. SPOTRNA predicts 2 pseudoknots connecting a single
stranded CUCAGGAA region to the stem structure that starts around position 70. Due to its size,
it was expected for the algorithms to generate predictions that bear little resemblance to each
other and that the 3D folding pattern of these molecules would be more discriminatory in
identifying the most realistic model/s.
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Figure 28. Secondary structure predictions for CSF1l. Dot bracket structure of predictions are indicated
below every figure. A. Centroidfold B. RNAFoldMFE C. RNAFoldCentroid D. RNAStructure E. SPOTRNA

6. p53 mRNA 5’ UTR (1324-1676) (P53l)
Using the 5 different algorithms, more than 30 predictions for secondary structure for this
molecule were generated. Since this is the largest RNA molecule investigated (355 nt), the
greatest degree of variation was observed as expected. SPOTRNA predicts 3 pseudoknots in 3
different regions that connects them to different parts of the big multi-loop structure.
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Figure 29. Secondary structure predictions for P53l. Dot bracket structure of predictions are indicated
below every figure. A. Centroidfold B. RNAFoldMFE C. RNAFoldCentroid D. RNAStructure E. SPOTRNA

In summary, the shorter molecules had more in common in the predictions from different
algorithms. Our results show that the longer the size of the mRNA UTRs, the more the variation
in the secondary structure predictions. The secondary structure predictions revealed that all
UTRs contained loop structures which could potentially serve as RNA recognition elements for
NCL-mRNA interactions. Note that secondary structure assignments are limited in identifying
other RNA recognition elements such as G quadruplexes or k-turns. G-quadruplex structures are
formed by stacking at least 2 G quartets that are linked together by three loops [24]. In silico tools
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such as QGRS mapper [25] have been developed to investigate these structures, but these
programs are primarily designed to identify these structures in DNA. The identification of these
structures is difficult in RNA due to the structural differences between RNA and DNA and how
the algorithms search for these motifs. The maximum allowed size of loops of 7 nucleotides is
not the most suitable criterion when investigating these structures [26] as the majority of loops
on mRNA UTR molecules identified in this study are greater than 7 nts.
B. 3D models of mRNA UTR molecules and selection of top models
1. CSF1 mRNA 3’ UTR (2921-2970) (CSF1s) model generation and evaluation
The Centroidfold model obtained the best scores in this group (Table 10). This model bears
resemblance with pri-miRNA molecules due to the presence of an apical loop and a double
stranded RNA region adjacent to the loop. RNAfoldcentroid and RNAfoldMFE models also
generated an apical loop in the same region as the Centroidfold model, as indicated by blue
circles in Figure 30 though both models exhibited an overall different folding pattern.
Table 10. Structural evaluation by MolProbity and ranking of all predicted CSF1S models according to
the criteria listed. Clashscore is the predominant criteria, although getting a lower score in every criterion
is desired. NB and NS stands for nucleobase and nucleoside refinement models generated by RNAFitme.

miRNA models

Clash
score

Probably
wrong sugar
puckers

Bad backbone
conformations

Bad
bonds

Bad
angles

CSF1 2921-2970
RNAFold MFE
RNAFold MFE NB
RNAFold MFE NS

8.45
3.02
1.21

0
0
0

6
6
6

0
0
1

0
5
18

RNAFold Centroid

17.51

0

3

0

0

Best in Top 3
Group overal
l

X

2nd
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RNAFold Centroid
NB
RNAFold Centroid
NS
RNAStructure
RNAStructure NB
RNAStructure NS
Centroidfold
Centroidfold NB
Centroidfold NS
SPOT-RNA
SPOT-RNA NB
SPOT-RNA NS
Vsfold5
Vsfold5 NB
Vsfold5 NS

3.62
1.21

0
0

3
3

0
6

6
30

11.47
8.44
6.03

1
0
0

20
20
20

0
0
10

0
8
75

29.59
4.22
0

0
0
0

1
1
1

0
0
2

0
7
11

12.08
8.44
1.81

1
0
0

10
10
10

0
0
7

0
6
38

9.06
5.43
7.84

0
0
0

17
17
17

0
0
20

0
8
89

X

3rd

X

1st

Figure 30: Top 3 models for CSF1S. Apical loops are indicated in blue circles. A. Centroidfold B.
RNAFoldCentroid C. RNAFoldMFE

2. IL-2 mRNA 5’ UTR (239-296) (IL2)
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SPOTRNA model obtained the best scores in this group, but it folds into an unusually relaxed
state. On the other hand, RNAfoldcentroid and Centroidfold models exhibited similar folding
states. Although all 3 models predict the first 20 nucleotides to be single stranded, SPOTRNA
model exhibits a different single stranded RNA folding pattern because of a pseudoknot that
connects the last 3 nucleotides to the first 3 nucleotides. Other high scoring RNAFoldCentroid
and Centroidfold models predicted the first part of the molecule as the same single stranded RNA
region but folding of the rest of the molecule differs.
Table 11. Structural evaluation by MolProbity and ranking of all predicted IL2 models according to the
criteria listed. Clashscore is the predominant criteria, although getting a lower score in every criterion is
desired. NB and NS stands for nucleobase and nucleoside refinement models generated by RNAFitme.

IL2 239-296

Clashscore

Bad backbone
conformations

Bad
bonds

Bad
angles

Best in
Group

21.29
8.72
3.82

Probably
wrong
sugar
puckers
2
0
0

RNAFold MFE
RNAFold MFE NB
RNAFold MFE NS
RNAFold Centroid
RNAFold Centroid
NB
RNAFold Centroid
NS
RNAStructure
Centroidfold
Centroidfold NB
Centroidfold NS
SPOT-RNA
SPOT-RNA NB
SPOT-RNA NS
Vsfold5
Vsfold5 NB
Vsfold5 NS

Top 3
overall

8
8
8

0
0
4

0
2
40

X

20.74
6
4.91

0
0
0

8
8
8

0
0
9

0
4
66

X

2ND

21.29
18.01
8.18
3.27
28.38
7.63
1.09
28.38
8.18
3.27

2
0
0
0
0
0
0
1
0
0

8
7
7
7
1
1
1
8
8
8

0
0
0
13
0
0
0
0
0
8

0
0
2
67
0
1
15
0
2
36

X

3RD

X
X

1ST

X
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Figure 31. Top 3 models for IL2. Apical loops are indicated in blue circles. A. SPOTRNA B. RNAFoldMFE C.
RNAFoldCentroid

3. p53 mRNA 5’ UTR (68-144) (p53s)
SPOTRNA model obtained the best scores overall in this group, but it folds in a very compact way
because of the pseudoknot that connects the multiloop to the region adjacent to one of the apical
loops. Nevertheless, all models include 2 apical loops on both ends of the molecule, as indicated
by blue and purple circles in Figure 32.
The Centroidfold model had second best clashscore and scored better than SPOTRNA model in 2
other sub-categories. Although no pseudoknot was predicted but 2 apical loops are suggested by
this model.
Table 12. Structural evaluation by MolProbity and ranking of all predicted P53s models
according to the criteria listed. Clashscore is the predominant criteria, although getting a lower
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score in every criterion is desired. NB and NS stands for nucleobase and nucleoside refinement
models generated by RNAFitme.
mRNA models

Clash
score

Probably
wrong sugar
puckers

Bad backbone
conformations

Bad
bonds

Bad
angles

Best in Top 3
Group overal
l

P53 68-144
RNAStructure
RNAStructure NB
RNAStructure NS

15.62
10.8
4.8

1
0
0

12
12
12

0
0
9

0
6
62

X

3RD

Centroidfold
Centroidfold NB
Centroidfold NS

14.82
9.6
5.6

0
0
0

14
14
14

0
0
1

0
4
39

X

2ND

SPOT-RNA
SPOT-RNA NB
SPOT-RNA NS

18.82
7.6
3.6

0
0
0

18
18
18

0
0
7

0
5
70

X

1ST

Vsfold5
Vsfold5 NB
Vsfold5 NS

26.43
9.2
6.4

5
0
0

44
44
44

0
0
20

0
8
122

Figure 32. Top 3 models for P53S. Apical loops are indicated in blue and purple circles. A. SPOTRNA B.
Centroidfold C. RNAFoldCentroid/RNAFoldMFE/RNAStructure
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4. BCL2 mRNA 3’ UTR (1772-1863) (BCL2)
RNAFoldMFE model obtained the best scores in this group. Although the predictions didn’t
identify any pseudoknots, the SPOTRNA model adopted a non-helical structure that was
different than the other 2 models. Although it scored lower than the RNAFoldMFE model,
RNAFoldCentroid model still exhibited very similar folding patterns compared to it. Both models
exhibited apical loop structures at both ends of the molecule, as indicated by blue and purple
circles in Figure 33.
Table 13. Structural evaluation by MolProbity and ranking of all predicted BCL models
according to the criteria listed. Clashscore is the predominant criteria, although getting a lower
score in every criterion is desired. NB and NS stands for nucleobase and nucleoside refinement
models generated by RNAFitme.
mRNA models

Clash
score

Probably
wrong sugar
puckers

Bad backbone
conformations

Bad
bonds

Bad
angles

15.23
8.12
3.72

1
0
0

20
20
20

0
0
11

0
3
80

RNAFold Centroid
RNAFold Centroid
NB
RNAFold Centroid
NS

16.58
8.45

4
0

21
21

0
0

0
5

4.73

0

21

19
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RNAStructure1
RNAStructure1 NB
RNAStructure1 NS

11.84
5.75
4.4

3
0
0

24
24
24

0
0
9

0
4
82

RNAStructure2
RNAStructure2 NB
RNAStructure2 NS

15.91
9.47
6.09

4
0
0

31
31
31

0
0
10

0
1
82

Bcl2 1772-1863
RNAFold MFE
RNAFold MFE NB
RNAFold MFE NS

Best in Top 3
Group overal
l

X

X
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Centroidfold
Centroidfold NB
Centroidfold NS

20.64
7.44
5.75

0
0
0

14
14
14

0
0
14

0
7
87

SPOT-RNA
SPOT-RNA NB
SPOT-RNA NS

18.95
4.4
1.35

1
0
0

8
8
8

0
0
6

0
2
44

Vsfold5
Vsfold5 NB
Vsfold5 NS

16.24
5.75
5.41

0
0
0

25
25
25

0
0
16

0
5
107

X

Figure 33. Top 3 models for BCL2. Apical loops are indicated in blue and purple circles. A. RNAFoldMFE B.
SPOTRNA C. RNAFoldCentroid

5. CSF1 mRNA 3’ UTR (3698-3860) (CSF1l)
SPOTRNA model obtained the best scores in all categories in this group. There is very little
structural resemblance amongst top 3 models, as indicated in Figure 34. Therefore, all models
were tested.
Table 14. Structural evaluation by MolProbity and ranking of all predicted CSF1l models according to
the criteria listed. Clashscore is the predominant criteria, although getting a lower score in every criterion
is desired. NB and NS stands for nucleobase and nucleoside refinement models generated by RNAFitme.
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mRNA models

CSF1 3698-3860
RNAFold MFE
RNAFold MFE NB
RNAFold MFE NS
RNAFold Centroid
RNAFold Centroid
NB
RNAFold Centroid
NS
RNAStructure1
RNAStructure1 NB
RNAStructure1 NS
Centroidfold
Centroidfold NB
Centroidfold NS
SPOT-RNA
SPOT-RNA NB
SPOT-RNA NS
Vsfold5
Vsfold5 NB
Vsfold5 NS

Clash
score

Probably
wrong sugar
puckers

Bad backbone
conformations

Bad
bonds

Bad
angles

27.97
13.02
4.98

4
0
0

28
28
28

0
2
10

1
6
96

18.2
9
2.68

3
0
0

24
24
24

0
0
3

1
8
69

22.99
10.72
4.4

3
0
0

24
24
24

0
0
5

0
6
77

17.82
6.32
3.26

0
0
0

32
32
32

0
0
8

14.18
5.74
1.34

2
0
0

16
16
16

26.05
15.32
10.72

5
0
0

47
47
47

Best in Top 3
Group overal
l

X

3RD

0
6
77

X

2ND

0
0
0

0
3
52

X

1ST

6
7
24

0
7
152

Figure 34. Top 3 models for CSF1l. A. RNAFoldMFE B. SPOTRNA C. RNAFoldCentroid
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6. p53 mRNA 5’ UTR (1324-1676) (P53l)
RNAStructurem5 model obtained the best scores in this group. Although all molecules adopted
a different folding state, certain structural elements such as the big multiloop structure exists in
all 3 models, as highlighted in Figure 35.
Table 15. Structural evaluation by MolProbity and ranking of all predicted P53l models according to the
criteria listed. Clashscore is the predominant criteria, although getting a lower score in every criterion is
desired. NB and NS stands for nucleobase and nucleoside refinement models generated by RNAFitme.

mRNA models

Clash
score

Probably
wrong sugar
puckers

Bad backbone
conformations

Bad
bonds

Bad
angles

62.6
39.91
25.55
15.92
15.21
5.13
8.31
4.33
10.61
5.57
9.02
4.51

0
0
0
0
0
0
0
0
0
0
0
0

55
55
55
55
71
71
68
68
82
82
75
75

318
291
23
55
13
15
1
25
0
26
0
22

869
678
105
319
25
193
19
251
18
222
17
240

Best in Top 3
Group overal
l

P53 1324-1676
Centroidfold NB
Centroidfold NS
RNAFoldMFE NB
RNAFoldMFE NS
RNAFoldCent NB
RNAFoldCent NS
RNAStructurem5 NB
RNAStructurem5 NS
RNAStructurem6 NB
RNAStructurem6 NS
RNAStructurem7 NB
RNAStructurem7 NS

X

1st

X

3nd

X

2nd
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Figure 35. Top 3 models for P53l. The central region of the molecule that contains a multiloop structure
adjacent to a double stranded RNA region is indicated in blue circles.

A. RNAStructureM5 B.

RNASTructureM7 C. RNAStructure M6

In summary, the algorithms utilized to predict the tertiary structure of the mRNA UTR molecules
tended to generate similar structures and folding patterns for the short mRNA UTRs with no
pseudoknots e.g., CSF1s and IL-2. When the sequence gets longer and/or pseudoknots are
predicted, then the overall folding patterns tend to be quite different among all algorithms e.g.,
P53l and CSF1l. BCL2 and p53s from the middle size group tend to show intermediate level of
variation. None of the algorithm predicts a pseudoknot in BCL2 but one is identified in p53s.
Certain RNA motifs such as apical loops were consistently identified in all p53s models although
the positions and sizes of these loops varied. Therefore, even when there is a clear top ranked
model in terms of its evaluation profile, all top 3 models were utilized in the RNA-protein docking
experiments to analyze all possibilities and look for similar trends in the interaction modes.
Despite the differences in the 3D models of each of the mRNA UTRs, we were able to identify
patterns of specificity of NCL RBDs for the various UTRs that corroborate experimental findings.
Docking analysis of mRNA UTRs with NCL RBDs reveals UTR specific NCL RBD-mRNA
interaction scenarios
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RNA-protein docking experiments conducted with the top three RNA models and top three NCL
RBD1-4 models yielded a total of 540 interaction scenarios, all of which were analyzed to glean
the consistent patterns in the results and suggest possible mechanisms of NCL RBD-mRNA
interaction. Overall, our results indicated a collaboration between RBD1-2 and RBD3-4 to
recognize mRNA UTRs. The details of our predictions and the most probable interaction scenarios
including interface residues in both mRNA UTRs and NCL are detailed below.
1. CSF1 mRNA 3’ UTR (CSF1s) is recognized by NCL through a collaboration of RBD1 with RBD4
or the tandem pair of RBD 3-4.
Analysis of docking results indicated that either RBD1 and RBD4 or RBD3 and RBD4 were
predicted to drive CSF1s-NCL interactions(Figure 36). The Centroidfold model-based scenarios
suggest that RBD3, RBD4, and RBD3-4 linker are the prime drivers of the interaction (Figure 36A).
The results indicate that residues on RBD3, RBD4 and the linker region connecting RBD3-4 were
identified to form the interaction interface. Aromatic and charged residues from RNP motifs on
RBD3 (K533, Y535, R564, E566) and RBD4 (R609, R614, F624) were the most frequently predicted
residues along with other residues from the RBD3-4 linker region (P574, N575, R577) as seen in
Figure 36B. Interestingly, many of these residues were also predicted in NCL-pri-miRNA
interactions. The RNAFoldCentroid model-based results suggest an alternate binding mode that
is comprised of RBD1, RBD4 and the RBD3-4 linker region defining the interaction interface with
this mRNA molecule (Figure36A). In this binding mode, aromatic residues from RNP motifs on
RBD1 (F326, F382) and other polar charged (E332, K343) and polar uncharged (N327, T335)
residues were predicted frequently. Previously identified residues (R607, F624) along with new
charged residues on RBD4 (D626, K656) constituted the other half of the interaction interface.
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Additional charged and polar uncharged residues from the linker region between RBD3-4 (R577,
S578) also contributed to the complex. RNAFoldMFE results, similarly, indicate that RBD1, RBD4
and the linker region between RBD3-4 are predicted to drive interactions with this mRNA
molecule. A similar set of residues have been predicted for this scenario as well: F326, N327,
E332, T335. K343, E371 and K387 from RBD1 and R607, F624, K656 from RBD4 were the residues
predicted with the highest frequency (Figure 36B). Previous experimental studies suggest that
there are 6 GGG regions in this sequence and that these GGG regions are important for the CSF1s
-NCL interactions. All models tested were predicted to interact with at least 2 or 3 of these regions
(Figure 36C). Overall, our results suggest that the top predicted group of residues includes 3 out
of these 6 GGG regions. The Centroidfold model results suggest an involvement of predominantly
A and G residues in these interactions. The RNAFoldCentroid model results suggests that a single
stranded RNA segment of the sequence towards the middle part of the molecule
(GCAAGGGAGGG) rich in G and A nucleotides was frequently predicted to interact with NCL RBDs.
2 out of 6 GGG sequences can be found in this region. The RNAFoldMFE model results resemble
those of the RNAFoldCentroid model where the residues most frequently predicted are almost
the same as the RNAFoldCentroid model and again in an A and G rich region (AGCAAGGGAGG).
2 out of 6 of the expected GGG sequences were part of the highly predicted residues.

87

Figure 36. CSF1s-NCL RBD interaction details A. Representative CSF1S-NCL RBD interaction scenarios of
1. Centroidfold 2. RNAFoldCentroid 3. RNAFoldMFE models. RNA residues are indicated in orange. RBD1
is in marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep olive. RBD2-3 linker is in
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yellow. RBD3-4 linker is in cyan. Interacting protein and RNA residues are indicated in hot pink and deep
teal, respectively. B. Multiple sequence alignment map of NCL RBD residues most frequently predicted to
drive CSF1s-NCL interactions. The type of interactions these residues are predicted to conduct are
indicated in colored boxes. Secondary structure motifs (beta strands and alpha helices) are indicated
below every alignment. C. Comparison of the most frequently predicted NCL interacting RNA residues of
CSF1S models of 1. CentroidFold 2. RNAFoldMFE 3. RNAFoldCentroid. Most frequently residues predicted
to interact with NCL are indicated in magenta. RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582656

2. IL-2 mRNA 5’ UTR (239-296) (IL2) is recognized by NCL through a collaboration of RBD1 and
RBD4 Analysis of docking results indicated that RBD1 and RBD4 were predicted to be the main
drivers of NCL-IL2 interactions in all IL2 models tested, as shown in Figure 37.
The SPOTRNA model was the highest scoring model overall, and due to the presence of the
pseudoknot that connects the first and last 3 nucleotides of the molecule, this model represents
a unique structural fold. Results indicate that many predicted residues are located between
positions 17-26 (ACUACUCACA). Results for the CentroidFold model indicate that a single
stranded RNA region at the beginning of the sequence between positions 4-13 (ACUCUCUUUA)
is the preferred binding site. Additional contact points have been identified on k-turns and
unpaired nucleotides as well. Results indicate that the RNAFoldCentroid model, similar to the
Centroidfold model contains a single stranded RNA region at the beginning of the sequence that
is preferentially recognized by NCL (UCUCUUUAAUC). This region also overlaps with a region in
the UTR that was identified in previous experimental studies. Additional contact points are
comprised of a few k-turns and unpaired nucleotides like the Centroidfold model results.
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There is some overlap in RBD, and linker residues predicted in the docking experiments for all 3
models of the IL2 UTR. The SPOTRNA model results indicate that N327, E332, F382, N384 from
RBD1, R607, R609, V611, K620, F622, F624 from RBD4 and S578 from the RBD3-4 linker region
are predicted to drive these interactions (Figure 37B1). Results for the Centroidfold model
docking experiments indicated that F326, N327, E332, K358 from RBD1 and V611, R614, K620,
F622, K656 from RBD4 form the key residues in the interaction interface (Figure 37B2). Lastly,
the RNAFoldcentroid model docking scenarios predict N323, F326, T335, K343, N384 from RBD1,
F585, K620, F622, K656 from RBD4 and N575, S578 from RBD3-4 linker region to be the most
frequently implicated residues to drive interactions with NCL (Figure 37B3).
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Figure 37. IL2-NCL RBD interaction details A. Representative IL2-NCL RBD interaction scenarios of 1.
SPOTRNA 2. RNAFoldMFE 3. RNAFoldCentroid models. RNA residues are indicated in orange. RBD1 is in
marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep olive. RBD2-3 linker is in yellow.
RBD3-4 linker is in teal. Interacting protein and RNA residues are indicated in hot pink and deep teal,
respectively. B. Multiple sequence alignment map of NCL RBD residues most frequently predicted to drive
IL2-NCL interactions. The type of interactions these residues are predicted to conduct are indicated in
colored boxes. Secondary structure motifs (beta strands and alpha helices) are indicated below every
alignment. C. Most frequently predicted RNA residues on IL2 models of 1. SPOTRNA 2. RNAFoldMFE 3.
RNAFoldCentroid. Residues most frequently predicted to interact with NCL are indicated in magenta.
RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582-656

3. p53 mRNA 5’ UTR (68-144) (p53s) is recognized by NCL through a collaboration of RBD1 and
RBD4 or the tandem pair of RBD3-4
Analysis of docking results indicated that either RBD1 and RBD4 (Figure 38A1, 3) or RBD3 and
RBD4 (Figure 38A2) form the putative modes of p53s-NCL interactions. The SPOTRNA model
results show that NCL-mRNA interactions are localized in G-rich regions and involve a few K-turns
and unpaired nucleotides. Short single stranded RNA regions rich in G, C and U were predicted
frequently to interact with NCL. Some k-turns and unpaired nucleotides were also predicted.
Results from the RNAFoldMFE model show a G-rich single stranded RNA regions may be
preferentially recognized by NCL. Additionally, this model predicted more than a few k-turns to
be hotspots for these interactions.
The residues found most commonly in the interaction interface for the 3 different UTR models
are as follows. The SPOTRNA model docking results indicate N325, F326, N327, K358 from RBD1,
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K599, V606, R607, V611, R614, E615, T616 from RBD4 and N575, S578 from RBD3-4 linker were
predicted to drive these interactions (Figure 39B1). The Centroidfold model docking results
indicate that K533, Y535, F543, E544, R564, E566, G253 from RBD3, R607, E615, S618 from RBD4,
and N575, R577, Q579 from RBD3-4 linker region were predicted to drive these interactions
(Figure 38B2). The RNAFoldMFE model docking results indicate that F326, N327, K358 from
RBD1, F585, R607, V611, R614, F622, F624, D626 from RBD4, and N575, S578 from RBD3-4 linker
region were predicted to drive these interactions (Figure 38B3). Again, there is some degree of
overlap in the predicted interface residues from the docking results of all the 3 UTR models.
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Figure 38. P53s-NCL RBD interaction details A. Representative P53S-NCL RBD interaction scenarios of 1.
SPOTRNA 2. Centroidfold 3. RNAFoldCentroid/RNAFoldMFE/RNAStructure models. RNA residues are
indicated in orange. RBD1 is in marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep
94

olive. RBD2-3 linker is in yellow. RBD3-4 linker is in teal. Interacting protein and RNA residues are indicated
in hot pink and deep teal, respectively. B. Multiple sequence alignment map of NCL RBD residues most
frequently predicted to drive P53s-NCL interactions. The type of interactions these residues are predicted
to conduct are indicated in colored boxes. Secondary structure motifs (beta strands and alpha helices) are
indicated below every alignment. C. Most frequently predicted RNA residues on P53s models of 1.
SPOTRNA 2. Centroidfold 3. RNAFoldCentroid/RNAFoldMFE/RNAStructure. Residues most frequently
predicted to interact with NCL are indicated in magenta. RBD1: 317-393, RBD2: 403-476, RBD3: 496-570,
RBD4:582-656

4. BCL2 mRNA 3’ UTR (1772-1863) (BCL2) is recognized by NCL through a collaboration of RBD1
and RBD4 or the RBDs 2-3-4 in tandem
Analysis of docking results revealed that either RBD1 and RBD4 (Figure 39A2) or RBD2-3-4 (Figure
39A1,3) were predicted to drive NCL-BCL2 interactions. This was the first time we observed that
3 RBDs were involved in the interactions. 9 G residues in the region tested (G3, G10/G11, G18,
G21, G27, G43, G44, G81), an AUUUA pentamer, an AUUUAUUUUUUA 12mer and an
AUUUAUUAUU 11mer sequence were predicted to be involved in these interactions. The
SPOTRNA model results indicate that 2 mini loops on the multiloop structure were preferred
targets of NCL. Additionally, 4 of the 9 G residues were part of the most frequently predicted RNA
residues. The RNAFoldMFE model results suggests that NCL prefers an AU rich region towards
the end of the sequence, although several other k-turns and unpaired nucleotides were also
frequently predicted to interact with NCL. Additionally, 4 of the 9 G residues were part of the
most frequently predicted RNA residues. The RNAFoldcentroid model results suggest that NCL
prefers a region at the beginning of the sequence and several other contact points that different
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RBDs are predicted to interact with. Again, 4 of the 9 G residues were part of the most frequently
predicted RNA residues. (Figure 39C).
Residues identified by the SPOTRNA model docking results include N327, P331, T335, D350 from
RBD1, K599, V606, R609, E641, E644 from RBD4, and N575, R577 from RBD3-4 linker region were
predicted as residues driving these interactions (Figure 39C1). The RNAFoldMFE model docking
results indicated that E438 from RBD2, N502, R561, R564 from RBD3, N575 from RBD3-4 linker,
R609, D613, R614, E615, T616 from RBD4 were predicted to drive these interactions (Figure
39C2). Lastly, the RNAFoldCentroid model docking results indicated that Y412, R467 from RBD2,
K523, N527, R564, E566 from RBD3, R571, N575, R577, Q579 from RBD3-4 linker, and E595, E596,
K599, F602, R607, N628, A635 from RD4 were predicted as residues driving the NCL-BCL2 UTR
interactions (Figure 39C3).
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Figure 39. BCL2-NCL RBD interaction details A. Representative BCL2-NCL RBD interaction scenarios of 1.
RNAFoldMFE 2. SPOTRNA 3. RNAFoldCentroid models. RNA residues are indicated in orange. RBD1 is in
marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep olive. RBD2-3 linker is in yellow.
RBD3-4 linker is in teal. Interacting protein and RNA residues are indicated in hot pink and deep teal,
respectively. B. Multiple sequence alignment map of NCL RBD residues most frequently predicted to drive
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BCL2-NCL interactions. The type of interactions these residues are predicted to conduct are indicated in
colored boxes. Secondary structure motifs (beta strands and alpha helices) are indicated below every
alignment. C. Most frequently predicted RNA residues on BCL2 models of 1. RNAFoldMFE 2. SPOTRNA 3.
RNAFoldCentroid. Residues most frequently predicted to interact with NCL are indicated in magenta.
RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582-656

5. CSF1 mRNA 3’ UTR (3698-3860) (CSF1l) is recognized by NCL through a collaboration of RBD1
and RBD4 or RBD2-3-4 in tandem
Analysis of docking results revealed that either RBD1 and RBD4 (Figure 40A3) or RBD2-3-4 were
predicted to drive CSF1l-NCL interactions (Figure 40A1,2). The SPOTRNA model was the best
scoring model and contains a large multiloop and a pseudoknot that connects this multiloop to
the single stranded region of the molecule. Results indicate that part of this region towards the
beginning that is rich in A and G residues, is predicted to drive these interactions. Additionally,
some unpaired nucleotides were predicted to be involved in these interactions as well. The
Centroidfold model results indicate that a region where 2 single stranded RNA regions are
adjacent to each other are preferentially recognized by NCL. Additional contact points have been
identified in some unpaired nucleotides. The RNAFoldCentroid model results indicate that NCL is
predicted to interact with a small stem loop structure that resembles a double stranded RNA,
and a short single stranded RNA region that lies adjacent to this region in 3D space. Again a few
k-turns and unpaired nucleotides have been identified as part of frequently predicted residues
(Figure 40C).
The SPOTRNA model binding mode revealed that these interactions are predicted to be driven
by RBD2, RBD3, RBD4, RBD2-3 linker and the RBD3-4 linker. Y412, E428, S438 rom RBD2, S492
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from RBD2-3 linker, Q526, K533, Y535, F537 from RBD3, R571 from RBD3-4 linker, D603, F627
from RBD4 were predicted to drive these interactions (Figure 40B1). The RNAFoldCentroid model
docking results revealed that N327, P331, E332, T335, D345 from RBD1, N575, R577, S578, Q579
from RBD3-4 linker, F585, R607, R614, S618, S619, K620, F622, K656 from RBD4 were predicted
to drive these interactions (Figure 40B2). The Centroidfold model docking results revealed that
E438 from RBD2, Q481 from RBD2-3 linker, L550, N551, N554, R564 from RBD3, R571, N575,
S578 from RBD3-4 linker, R614, K620, F622 from RBD4 were predicted to drive these interactions
(Figure 40B3).
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Figure 40. CSF1l-NCL RBD interaction details. A. Representative CSF1l-NCL RBD interaction scenarios of
1. SPOTRNA 2. Centroidfold 3. RNAFoldCentroid models. RNA residues are indicated in orange. RBD1 is in
marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep olive. RBD2-3 linker is in yellow.
RBD3-4 linker is in teal. Interacting protein and RNA residues are indicated in hot pink and deep teal,
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respectively. B. Multiple sequence alignment map of NCL RBD residues most frequently predicted to drive
CSF1l-NCL interactions. The type of interactions these residues are predicted to conduct are indicated in
colored boxes. Secondary structure motifs (beta strands and alpha helices) are indicated below every
alignment. C. Most frequently predicted RNA residues on BCL2 models of 1. RNAFoldMFE 2. SPOTRNA 3.
RNAFoldCentroid. Residues most frequently predicted to interact with NCL are indicated in magenta.
RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582-656

6. p53 mRNA 5’ UTR (1324-1676) (P53l) is recognized by NCL through a collaboration of all RBDs
and linker regions
Analysis of docking results for NCL -P53l interaction revealed that all RBDs and all linker regions
except RBD1-2 linker were predicted to be the drivers of P53l-NCL interactions, as indicated in
Figure 41A. The RNAStructurem5 model results indicate that the majority of predicted
interactions were identified on a big multiloop structure and a small double stranded RNA region
adjacent to that multiloop structure. Other top scoring models displayed different folded
structures, but they all contained a large multiloop structure and a short double stranded RNA
region adjacent to it. Common to all the results are NCL-mRNA interactions localized to G-rich
regions. Additional k-turns and unpaired nucleotides were also identified in this binding mode.
Interestingly, highly frequently predicted residues were localized around a short double stranded
RNA region that is adjacent to a big multiloop structure, which was modeled in all the 3 structures
tested (Figure 41C). Docking results indicate that all RBDs and RBD linker regions except for RBD12 linker are predicted to be involved in these interactions.
The RNAStructure M5 model docking results indicate that E365 from RBD1, E438 from RBD2,
K477, N480, Q481, N488 from RBD2-3 linker, K547, L550, N551, K555 from RBD3, P571, N575,
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R577 from RBD3-4 linker, E595, R609, R614, S618 from RBD4 were predicted to drive these
interactions (Figure 41B1). The RNAStructure M6 model docking results indicate that F326, N327,
E332, F382 from RBD1, E444, K446 from RBD2, T490 from RBD2-3 linker, N529, K531, from RBD3,
N575, R577, S578 from RND3-4 linker, F585, K620, R607, R609, F622, F624, K656 from RBD4 were
predicted to drive these interactions (Figure 41B2). The RNAStructure M7 model docking results
indicate that E371, V381, F382 from RBD1, Q460, Y472, E438 from RBD2, Q481 from RBD2-3
linker, E566 from RBD3, N575, R577 from RBD3-4 linker, R614, N628 from RBD4 were predicted
to drive these interactions (Figure 41B3).
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Figure 41. P53l-NCL RBD interaction details. A. Representative P53l-NCL RBD interaction scenarios of 1.
RNAStructureM5 2. RNAStructureM7 3. RNAStructureM6 models. RNA residues are indicated in orange.
RBD1 is in marine blue, RBD2 is in deep salmon, RBD3 is in light blue, RBD4 is in deep olive. RBD2-3 linker
is in yellow. RBD3-4 linker is in teal. Interacting protein and RNA residues are indicated in hot pink and
deep teal, respectively. B. Multiple sequence alignment map of NCL RBD residues most frequently
predicted to drive P53l-NCL interactions. The type of interactions these residues are predicted to conduct
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are indicated in colored boxes. Secondary structure motifs (beta strands and alpha helices) are indicated
below every alignment. C. Most frequently predicted RNA residues on P53l models of 1. RNAStructurem5
2. RNAStructurem7 3. RNAStructurem6 Residues most frequently predicted to interact with NCL are
indicated in magenta. RBD1: 317-393, RBD2: 403-476, RBD3: 496-570, RBD4:582-656

Discussion
Identification of RBD and residue specificity in NCL-mRNA UTR interactions
Results of NCL-mRNA UTR docking interactions revealed the most frequently predicted residues
in each NCL RBD. This analysis allowed us to identify which of the four NCL RBDs are predicted to
drive these interactions and which residues on the RNA molecules are involved. Comparison of
this information with what was established in the literature allowed us to evaluate our
predictions and generate potential NCL-mRNA binding modes. Each of the mRNA UTR results are
discussed in detail first and then the overall big picture of NCL – mRNA interactions are presented.
CSF1s mRNA UTR -NCL interactions
NCL interacts with CSF1 3’ UTR mRNA. Overexpression of NCL leads to increased de-adenylation
of this molecule and reduced levels of steady state expression but also increases the translation
rates [18]. Mutational analysis has shown that NCL shows a high affinity towards G-quadruplex
structures found in this region [18]. 6 GGG sequences found in this region were expected to
interact with NCL and our docking results indicate that all tested models were able to at least
bind to 2 and in some cases 3 of these 6 motifs. It has been established that the 4 th of the G
quadruplex structures in this region of CSF1 mRNA UTR is deemed the most critical of the 6
regions tested with mutational experiments [18]. The interactions between NCL RBDs and CSF1
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mRNA are abolished when this region was mutated from GGG to UUU similar to the experimental
study [18]. Although, docking scenarios do not predict specific affinity for this region, that may
be due to limitations in our models to model the G quadruplex structures in the UTR. However,
the UUU mutation modeled in the RNA UTR sequence dramatically impacts the secondary and
tertiary structure and the mutated sequence adopts a very different three-dimensional state
(Figure 42). It is possible that the disruption of the NCL-mRNA interactions could be a
consequence of a misfolded structural state of the UTR.

Figure 42. Comparison of the mutated and wild type CSF1s UTR. A.UUU mutation modeled in CSF1s UTR.
The mutated residues are colored magenta. B. Wild type CSF1s UTR. The wild type residues, GGG are
colored magenta
There is complete lack of information regarding NCL RBD specificity for binding to the CSF1 3’ UTR. Based
on our docking analyses, we have identified RBD1, RBD4, and RBD3-4 linker region as components that
may be predominantly responsible for interaction with the CSF1 3’ UTR. An alternative scenario stemming
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from the results of the Centroidfold model suggest involvement of only RBD3 and RBD4 along with the
linker region between the two RBDs.

IL2 mRNA UTR-NCL interactions
NCL interacts with 5’ UTR of IL2 mRNA and this interaction is required for this mRNA molecule to
be stabilized by proteins from the JNK mitogen-activated protein kinase (MAPK) pathways [145].
Studies from the literature suggest that the region containing nucleotides 3-22 is critical for these
interactions. Our docking results corroborate this finding, and this critical region is indeed
predicted to be recognized by NCL in all models tested Figure 37C. It is also interesting to note
that this region is almost exclusively single stranded in 2 out of the 3 models, since NCL is known
for its affinity for double stranded RNA molecules. Although no specific information regarding
NCL RBD specificity was available in the literature, we have identified a possible binding mode
consisting of RBD1, RBD4, and RBD3-4 linker region, as indicated in Figure 37A.
IL-2 mRNA has a very short half-life and is prone to degradation. This is in line with our results of
the prediction of a long single stranded RNA in both the RNAFoldMFE and RNAFoldCentroid
models. In both cases, NCL RBDs cover the area surrounding this region to a large extent. If NCL
RBDs indeed interact with IL2 as depicted in these models, NCL can potentially shield this
molecule from degradation and therefore increase translation rates. Consequently, tumor
suppressor p27 and p21 would be suppressed by increased IL-2 levels.
p53s mRNA UTR-NCL RBD interactions
SPOTRNA and RNAFoldMFE results revealed a binding mode that is comprised of RBD1, RBD3-4
linker and RBD4 as the predominant one for this molecule. Alternative results obtained from
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CentroidFold model indicate that the binding mode that is comprised of RBD3, RBD3-4linker, and
RBD4. Both binding modes are visualized in representative scenarios in Figure 38A. Previous
studies have suggested that RBD1-2 might be able to weakly bind to p53s. Our docking results
revealed that a combination of elements from RBD1-2 and RBD3-4 were predicted together to
drive these interactions.
NCL interacts with p53 mRNA 5’ UTR and these interactions result in suppression of translation
of p53. RPL26 also interacts with p53 mRNA 5’ UTR but this interaction promotes p53 translation.
Studies have shown that there is a 20-nucleotide sequence on the p53 mRNA 5’ UTR (22-43 in
the sequence) that RPL26 preferentially interacts with. NCL also interacts with RPL26, and this
interaction disrupts the translational upregulation of p53 by RPL26. Our docking results show
that NCL is predicted to also interact with this region of p53 mRNA UTR in all models tested,
which suggests a competitive inhibition mechanism exerted by NCL on RPL26 (Figure 43A).
Control docking experiments conducted with the RPL26 alphafold model and the generated p53
5’ UTR models showed that RPL26 was predicted to interact with this 20 nt region as noted in the
experimental study [19] (Figure 43B). To investigate the molecular mechanisms of NCL-RPL26
interactions and how these interactions could lead to suppression of molecular functions of
RPL26, we performed protein-protein docking experiments of p53 mRNA UTR and NCL complex
with RPL26 alphafold model. Results of docking experiments revealed that RBD2, RBD3, and RBD4
were predicted to drive these interactions in contrast to NCL – p53 UTR alone where RBD1, RBD4
and RBD3-4 linker regions were predicted to drive the interactions (Figure 43C) suggesting that
the NCL – p53 UTR interaction leaves RBD2 and RBD3 available for interactions with other
molecules, including RPL26. We asked if such a binding mode was possible, and results of docking
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experiments with both proteins in presence of p53 mRNA UTR indeed generated a scenario
where NCL was predicted to interact with p53s through RBD1, RBD4, RBD3-4 linker and with
RPL26 through RBD2 and RBD1-2 linker (Figure 43C). These results strongly suggest that NCL is
capable of sequestering RPL26 protein and occupy a region on p53s that is targeted by RPL26.
NCL, therefore can potentially inhibit translation of p53 by competitively binding to a region
required by RPL26 to effectively enhance p53 translation.

Figure 43. Representative interaction scenarios for A. p53s-NCL B. p53s-RPL26 C. p53s-NCL-RPL26
interactions. RNA residues are indicated in orange. RBD1 is in marine blue, RBD2 is in deep salmon, RBD3
is in light blue, RBD4 is in deep olive. RBD2-3 linker is in yellow. RBD3-4 linker is in teal. Interacting protein
and RNA residues are indicated in hot pink and deep teal, respectively.

BCL2 mRNA UTR -NCL RBD interactions
We were able to identify 2 alternative binding scenarios in this set of results. The first binding
mode consists of RBD1, RBD4, and RBD3-4 linker region, as predicted for the SPOTRNA model
results. This binding mode mimics the docking results of the shorter mRNA UTR dockings (IL2,
CSF1s, p53s). In contrast, in the case of RNAFoldMFE and RNAFoldCentroid model docking results,
RBD2, RBD3, RBD4, and RBD3-4 linker region were predicted to be part of the interaction
interface. Both binding modes are visualized by representative scenarios in Figure 39A. This is
108

the first case in which 3 RBDs were predicted to cooperate to drive NCL-mRNA UTR interactions.
BCL2 is one of the longer UTRs tested; an increase in the size of the molecule leads to an increase
in potential interaction interface size. Previous studies have shown that RBD1-4+RGG did show
an affinity for this region that is comparable to the results obtained RBD1-2+RGG. Additional data
indicated that RBD3-4+RGG exhibited an affinity that is 5 times lower than RBD1-2+RGG [58]
suggesting a more prominent role for RBDs 1-2 in this interaction. Interestingly, our results do
not predict this dominant involvement of RBD1-2 over RBD3-4, but rather a collaboration
between them although our models differ from the constructs in the study which also include
the RGG domain.
NCL interacts with a 91 nt stretch in BCL2 mRNA 5’ UTR with high affinity based on results from
previous studies. Experimental data suggests that 9 guanine residues in this stretch bind to NCL
and an AU rich 11mer is predicted to interact with NCL [59]. Our docking results revealed that at
least 4 of these 9 G residues were predicted to be part of the interaction interface in all models
tested. However, the 11mer was predicted to be part of the interaction interface only in the case
of the SPOTRNA model.
CSF1l mRNA UTR NCL RBD interactions
NCL interacts with this 162 nt long region on CSF1 mRNA UTR 3’. Overexpression of NCL leads to
paradoxical outcomes including an increase in deadenylation dependent mRNA decay and
enhanced translation rates that lead to increased total protein levels [18]. It has been shown that
only NCL RBDs lead to a dramatic increase in CSF1 mRNA levels and a moderate increase in CSF1
protein levels when compared to the full length NCL protein. The C-terminal and N-terminal
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truncated proteins leads to decreased mRNA levels. Although individual RBDs have not been
investigated in this study, NCL RBDs are critical in keeping CSF1 mRNA levels high [18]
Our results indicate a strong cooperation between RBDs and linker regions (Figure 40A). By doing
so, NCL is potentially able to extend the interaction interface area that it can regulate by
interacting with multiple and distant parts of the RNA molecule simultaneously. According to the
docking results, two possible binding modes were identified (Figure 40A). The first binding mode
consists of RBD1, RBD4, and RBD3-4 linker, based on RNAFoldCentroid model results and follows
the pattern of the binding mode observed in all previous UTR docking results (IL2, CSF1s, p53s,
and BCL2). The Centroidfold and SPOTRNA model docking results, however, suggest the
involvement of RBD2, RBD2-3 linker, RBD3, RBD3-4 linker and RBD4 in the interaction. This the
first instance where RBD2-3 linker was predicted to be part of the interaction interface in NCLmRNA UTR interactions.
Additionally, all docking results indicated that the profile of interacting residues are slightly
different when compared with results from other mRNA UTR docking scenarios. Overall, a lower
number of salt bridges were observed for interactions with this specific UTR. The Centroidfold
model alone picks up a short double stranded RNA sequence to be involved in the interactions.
In all other cases, the interactions were observed only in single stranded RNA regions. An
interesting feature of this interaction is that K-turns and unpaired nucleotides were predicted to
be part of the binding scenarios.
P53l mRNA UTR NCL RBD interactions
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Our results indicate that all RBDs and linker regions were predicted to be involved in NCL-P53l
interactions as well, as indicated in Figure 41A. In all scenarios, RBD4 was identified as the
dominant RBD and contributed with the highest number of binding interface residues. Previous
studies suggest that a construct comprising of NCL N-term+RBD1-2 is incapable of interacting
with P53l. NCL RBD-P53l docking results suggest a coordinated organization between all RBDs
and that RBD1-2 alone would be insufficient to drive these interactions. Therefore, our findings
affirm information from this study. Although the arginine residues from RBD4 were consistently
and frequently predicted in all tested UTR models, the profile of the residues and motifs exhibit
a larger variation that was observed for the other UTRs. Several new residues not previously seen
were consistently identified to constitute a major part of the interaction interface in NCL-P53l
interactions.
Table 16 summarizes the overall findings for the mRNA UTRs analyzed in this study and their
correlation with previous experimental studies. The findings from our analysis affirmed structural
information derived from experimental studies on NCL-IL2 and NCL-CSF1s (the short-sized UTR
group) interactions to a large extent. Results for NCL-p53s and NCL-BCL2 interactions (the middlesized UTR group) indicate that expectations established from prior studies are partially satisfied
since our results didn’t exhibit binding modes dominated by RBD1-2, but rather a collaboration
between RBD1-2 and RBD3-4. However, predictions of interacting RNA residues were
corroborated for this group of UTRs. Results of NCL-CSF1l and NCL-P53l interactions (the longsized UTR group) indicate that predictions met expectations established from prior studies, as in
both cases all 4 RBDs were revealed to be critical for these interactions. Interestingly, the P53l
docking results revealed the predicted RNA-protein interaction interface to be around the same
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region in all models even though the general structure and folding pattern of the mRNA UTR
molecules were distinct.
Table 16. Summary of docking result evaluation compared with information from the literature

Potential NCL-mRNA UTR binding modes
Using 3D RNA and protein models generated in this study, we were able to generate predicted
NCL RBD- mRNA UTR interaction scenarios. Using these scenarios, we present 3 main binding
modes that describe the overall patterns of NCL RBD- mRNA UTR interaction for the mRNA UTRs
analyzed in this study (Figure 44). The first and the predominant binding mode consists of RBD1,
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RBD3-4 linker and RBD4. This binding mode exhibits high affinity towards single stranded RNA
regions and has been observed in all mRNA UTR molecule except for P53l. The deviation in the
results for P53l with a predicted involvement of all RBDs is not unexpected due to its size and
complexity in folding pattern.
An alternative binding model, which involves the role of RBD3, RBD3-4 linker and RBD4 was
identified in the scenarios of a few mRNA UTR molecules (CSF1s, p53s). This binding mode
suggests a key role of double stranded RNA regions in the modeled UTRs, which are placed
adjacent to apical loop structures, signature motifs for NCL-RNA interactions.
The final putative binding mode was identified in scenarios of NCL interactions with long mRNA
molecules (BCL2, CSF1l, P53l), where more RBDs are involved in these interactions. The tandem
pair of RBD2-3-4 were frequently predicted together in both NCL-BCL2 and NCL-CSF1l
interactions, and all RBDs were predicted to be involved in NCL-P53l interactions. Interestingly,
although the RBD2-3 linker was often involved in the interaction interface, the RBD1-2 linker
wasn’t predicted to be involved in any of these interactions. This binding mode was only exhibited
by the larger and complex mRNA UTR molecules as a potential mode of interaction.
Finally, the RBD3-4 linker was predicted to be part in all tested molecules and models. Similarly,
RBD4 was always played a dominant role in all NCL – mRNA UTRs analyzed in this study.
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Figure 44. Potential NCL mRNA UTR binding modes

Previous studies in the literature investigating the specificity of RBDs have been limited to
truncating whole RBDs and testing them as tandem pairs of RBDs (RBD1-2 or RBD3-4) but this
approach reduces the complexity of the interactions that NCL can achieve by utilizing different
combinations of its 4 RBDs and the linker regions that connect these RBDs. Therefore RBD1-2
constructs tested in these studies exhibit a weak or negligible affinity towards mRNA UTR
molecules. An In-silico modeling approach has allowed us to generate predictions that
demonstrate a collaboration between RBD1-2 and RBD3-4 in all models. The main binding mode
predicted in our results that contains RBD1, RBD3-4 linker, and RBD4 could not have been
114

identified with traditional wet-lab methodologies that focus on truncating whole RBDs to tandem
pairs of RBDs. This computational approach also afforded us to generate a detailed list of residues
highly likely to be involved in these interactions. This sets the stage for rationally designing
experiments to validate the predictions through mutational studies that can target individual
residues. Verification of the involvement of these residues in NCL-mRNA UTR interactions is
critical and lays the foundation for designing therapeutical applications in human cancers where
these interactions play a role.
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Chapter 4: NCL-NCL oligomerization
Introduction
RBPs functions are primarily carried out via interactions with RNA molecules through their RNA
binding domains [22]. Some RBPs are capable of oligomerization and this capability allows them
to interact with some of their targets in a context-based manner. For example, Human Antigen
R (HuR) is an RBP that contains 3 RBDs and utilizes its third RBD for the purposes of
oligomerization [156]. The first 2 RBDs are in tandem in the sequence but RBD3 is located at the
C-terminus, fairly distant from the other 2 RBDs. This RBD3 is not known to interact with RBD12, but with RBD3s in other copies of the protein, thereby mediating oligomerization of HuR. This
oligomerization has been established as critical for allowing HuR to interact with some of its
targets which includes RNA sequences rich in AU regions [156]. Another study has also shown
that HuR is capable of oligomerization through RBD1, but only in the presence of a compatible
nucleotide sequence. An additional study has revealed that although RBD1 of HuR was required
for this oligomerization, Poly (ADP-ribosyl)ation (PARylation) of certain residues promotes both
oligomerization and HuR’s functions of binding and upregulating translation of CXC motif
chemokine ligand 2 mRNA (CXCL2) [157]. CXCL2 is an important cytokine involved in
inflammation processes [158]. Therefore, HuR oligomerization may be mediated by its RBDs in
conjunction with PTMs although the molecular mechanisms of these processes are still quite
understudied [156,157].
Besides RBDs, glycine arginine rich domains are also known to interact with RNA molecules and
involved in oligomerization processes. These domains are categorized according to how many
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Arg-Gly (RG) or Arg-Gly-Gly (RGG) repeats exist in a protein sequence and how far apart they
are dispersed within the domain boundaries [159]. A gene ontology study deciphered that RBDs
with more RGG domains (Tri-RGG) have increased RNA binding capabilities [159]. Both HNRNP
A1 and NCL were identified to belong to the Tri-RGG category [159]. In fact, NCL RGG domain
contains 9 RGG repeats, more than any other RBD investigated in the same category. Serine
and arginine rich splicing factor 2 (SRSF2) is another example of a RBP that contains 1 RBD and
an arginine-serine rich domain. Due to the net positive charge of its arginine-serine rich
domain, dephosphorylated SRSF2 was shown to aggregate, and losing its RNA binding functions
in this aggregated form [160]. In summary oligomerization can serve as an important element
of target recognition by RBPs. Depending on the nature of these interactions, oligomerization
interactions can either promote or suppress RBP functions. Therefore, these modes of
oligomerization need detailed investigation in the correct context to elucidate their impact on
functions of their RBPs.
NCL oligomerization
Some NCL functions also require NCL to be in an oligomerized state. NCL is known to interact
with p53 mRNA, and this interaction results in translational suppression of p53 [19]. It has now
been established that NCL oligomerization is critical for p53 suppression and the contributions
of individual NCL domains to the oligomerization and translational repression functions have
been mapped out. NCL RBDs are capable of oligomerization and suppressing p53 translation,
similar to the full length (FL) NCL protein. The C-terminus is also involved in oligomerization.
The N-terminus on the other hand abrogates both oligomerization and translational
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suppression functions of NCL [19]. It has also been shown that NCL phosphorylation is critical
for oligomerization and other functions of NCL [48].
Although RBDs have been shown to be critical in NCL oligomerization, and the RGG domain is
known to contribute to it, the molecular details of the oligomerization including the residues
important for stabilizing the complex are unknown and have not been investigated.
Additionally, the impact of NCL dimerization on its RNA binding functions has been investigated
only to a limited extent. Current experimental tools are limited in their ability to probe these
molecular details and downstream implications until structures of the NCL dimerized state
become available. This chapter addresses this gap of knowledge in the molecular mechanisms
driving NCL dimerization by using in silico tools. Here, we present dimerization models of a
central domain+RGG domain construct modeled using ab initio approaches. These predictions
of dimerization scenarios allowed us to identify frequently predicted residues driving these
interactions. In addition, we probed if the predicted NCL dimers can interact with p53 3’ UTR, a
known target of an NCL dimer. Our results provided preliminary insight into possible
oligomerization modes of NCL, and residues predicted to drive this process. We were also able
to predict a binding mode of an NCL dimer to interact with p53 3’ UTR.
Methods
A flowchart summarizing the general protocol of the present study with the various tools used to
analyze NCL-NCL dimerization interactions (discussed in detail later) is shown below in Figure 45.
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Figure 45. Flowchart depicting the methods and tools utilized in this chapter. Individual steps and
programs/algorithms utilized in those steps are indicated in blue and white boxes, respectively

Sequence analysis, and generation of 3D models of NCL FL and NCL partial protein
Since NCL FL crystal structures and NCL FL homologs are not available in the literature, 3D
models of NCL FL were generated using ab initio tools. For modeling, evaluation, and
refinement steps, please refer to the methodology section of Chapter 2. Partial NCL models
were also generated using the same algorithms listed in the flowchart. Assembly/fusion of
these truncated proteins was performed using DEMO [161]. DEMO is an algorithm for protein
domain assembly, and the merging process is guided by information derived from
experimentally defined protein complexes from public databases.
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Disorder analysis and prediction of motifs involved in NCL-mRNA interactions
Disordered region analysis was conducted using Prdos [162], PSIPRED [163], and IUPRED2A
[164]. Final NCL models were used as inputs for protein-protein interactions algorithms, HDOCK
[115] and ClusPro [165]. Each program yielded 10 scenarios per experiment. 60 interactions
scenarios were generated and analyzed in total, and the most frequently predicted residues
were identified.
Results
As discussed in the introduction, previous studies investigating NCL-NCL interactions have
revealed that the RBDs and the RGG domain were responsible for oligomerization interactions
but the extent of the coordination and interplay of individual domains and make up of residues
constituting the interaction interface are still unknown. Results from our docking experiments
have revealed predictions for NCL-NCL dimer interactions, which allowed us to generate
different binding modes that potentially represent different stages of the dimerization process
(described later).
Prediction of disordered regions in NCL
The central structured RBD containing region of NCL is flanked by the acidic domain at the Nterminus and the RGG domain at the C-terminus. To assess if these regions are structured or
intrinsically disordered, we analyzed the prediction of disordered region within NCL. The results
indicate that NCL RBDs were highly structured with disorder predicted for only the linker
regions between RBDs as expected. However, both termini, especially the acidic domain, were
predicted to exhibit very high scores of disorder prediction as indicated in Figure 46.
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Additionally, both termini, especially the acidic domain, were predicted to have high disordered
region binding scores. This score represents the tendency to be able to interact with other
globular proteins.

Figure 46. Prediction of intrinsically disordered regions in NCL. A. Prdos B. PSIPRED C. IUPRED2A.
Disorder thresholds are indicated with red and grey lines in Prdos and IUPRED2A, respectively. The red
line in IUPRED2A represents disorder tendency score while blue line represents the tendency of being a
disordered region involved in binding. Acidic domain, RBD and RGG domains are indicated in blue, green
and yellow circle and rectangles, respectively.

Full length NCL models
To analyze the possible structural details of the dimerized NCL our initial strategy was to
generate a full-length model of NCL. Using all available ab initio modeling approaches, we
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attempted to model the full length NCL. Unfortunately, since both the acidic domain and the
RGG domain are highly disordered, all generated models were of extremely low quality (Table
17) and adopted unrealistic structures in the disordered regions, as indicated in Figure 47,
resulting in a failed attempt to generate a complete structural representation of NCL. Although
the NCL FL composite Alphafold model scored higher than our FL models in general and looked
more realistic, it still exhibited quite low scores in the disordered regions and therefore could
not be used as a viable option for docking as well (Figure 47D).

Figure 47. Full length NCL models. A. Robetta model B. Intfold model C. I-tasser model D. Alphafold
model
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Table 17. Model evaluation of NCL FL models.

* Results not obtained due to server unavailability
Individual models of the NCL terminal regions
Our next approach was to model the acidic domain and the RGG domain separately to build a
composite full-length model by combining the individual modeled regions of NCL. However, the
models obtained also did not score well (Tables 18 and 19) especially the acidic domain which
had the lowest scores. Consequently, the models which were obtained by fusion of the
individually modeled domains also scored low on average even though the central domain with
the highly structured RBDs scored very well in evaluation programs. Therefore, this approach
also failed to yield a realistic full length structural model of NCL.
Table 18. Model evaluation of NCL N-terminus models.
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Figure 48. NCL N-terminus models A. Robetta model B. Intfold model C. I-tasser model.
Table 19. Model evaluation of NCL C-terminus models.
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Figure 49. NCL C-terminus models A. Robetta model B. Intfold model C. I-tasser model.

3D Model of RBD+RGG (NCLMC)
Since the acidic domain is known to abrogate oligomerization, our next approach was to omit
the N-terminal domain. 3D models of RBD+RGG (NCLMC) were generated using ab initio
approaches and these models exhibited an overall more realistic structural fold (Figure 50)
which matched their much better evaluation profiles (Table 20). Therefore, the NCLMC models
were chosen as the best option to proceed with protein-protein docking to generate scenarios
of a dimerized NCL.
Table 20. Model evaluation of NCLMC models.
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Figure 50. NCLMC models A. Robetta model B. Intfold model C. I-tasser model.

NCL full length composite model
Since our attempts at getting a full length NCL model were insufficient in generating a realistic
model with a high-quality score, we generated a composite model that contains best scoring
models from each domain modeling attempt. Structural information on RBDs were extracted
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from the alphafold model. Although the model exhibited low scores on average, the highly
structured RBDs were of high quality. Models of 3 NCL domains were fused using DEMO.
Unfortunately, this model also exhibited unrealistic folding patterns as seen in Figure 51 and
obtained low scores in evaluation steps (Table 17). Therefore, it wasn’t used in docking
experiments.

Figure 51. NCL Full length composite model.

NCL dimerization
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Since all final models exhibited differences in the modeled quaternary structural folds, the
docking experiments yielded varying results, which was expected. Nevertheless, binding modes
identified in docking algorithms were consistently predicted by both docking algorithms.
1. NCLMC Intfold model oligomerization
Docking results of the Intfold NCLMC model suggests a scenario where the oligomerization is
predicted to be driven by RGG domains only, since they are the part of the model that form the
interaction interface. RBDs don’t make any contact in this binding mode as they are positioned
far away from each other, as indicated in Figure 52.

Figure 52. Representative models of NCLMC Intfold model dimerization mode as predicted by A.
HDOCK and B. ClusPro. NCL1RBD is indicated in cyan. NCL1RGG is indicated in hot pink. NCL2RBD is
indicated in green. NCL2RGG is indicated in orange

2. NCLMC I-tasser model oligomerization
Docking results of the I-tasser NCLMC model suggest that the oligomerization is predicted to be
driven by both the RGG and RBD domains. RGG-RGG interactions predominate the interaction
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interface but there is a contribution of RGG-RBD interactions to stabilize the complex in this
binding scenario (Figure 53).

Figure 53. Representative models of NCLMC I-Tasser model dimerization mode as predicted by A.
HDOCK and B. ClusPro. NCL1RBD is indicated in cyan. NCL1RGG is indicated in hot pink. NCL2RBD is
indicated in green. NCL2RGG is indicated in orange

3. NCLMC Robetta model oligomerization
The Robetta NCLMC model generated docking results that predict the dimerization is driven by
both RBD and RGG domains also. However, in this scenario there is a shift of interactions that
allows more RGG-RBD interactions as well as numerous RBD-RBD interactions. Interestingly
RGG-RGG interactions were not observed in this binding mode (Figure 54).
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Figure 54. Representative models of NCLMC Robetta model dimerization mode as predicted by A.
HDOCK and B. ClusPro. NCL1RBD is indicated in cyan. NCL1RGG is indicated in hot pink. NCL2RBD is
indicated in green. NCL2RGG is indicated in orange

In summary, since the top 3 NCLMC models differ in their 3D structure, especially in the RGG
domain, the predicted oligomerization modes were also different. These differences were
observed in the distance between domains, and the number and type of interactions that hold
them in place.
Molecular details of NCL dimerization
Intfold results show that a group of Arg and Phe residues in the RGG domain were predicted to
be key to the dimerization scenario in addition to an overall large contribution of non-bonding
interactions. The least number of salt bridge interactions were observed in this mode since
RBDs were not predicted to contribute much to these interactions, as indicated in Figure 55.
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Figure 55. Docking scenario representing NCL Intfold model dimerization binding mode. A. Complete
docking scenarios. B. Zoomed in version with individual residues highlighted in blue. C. Summary of
intermolecular interactions, obtained by PDBSUM. Orange, blue, and red lines represent non-bonding,
h-bonding, and salt bridge interactions, respectively

I-tasser results indicated that a similar group of Arg and Phe, and Gly residues in the RGG
domain were predicted to be the predominant drivers of the interaction. The non-bonding
interactions were again prevalent in this binding mode but there was a noticeable increase in
interactions driven by residues on RBDs. Results also indicated that more salt bridges were
predicted to be initiated in these scenarios, and RBDs were predicted more often to be involved
in these important stabilizing interactions. In fact, RBD-RGG interactions were predicted to be
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predominant in this binding mode. A few charged residues on RBD4 (R614, E615) were
consistently predicted to play a key role in stabilizing the dimerized complex. Additionally,
some residues from RBD3-4 linker (R577, P580, and Q579) were also consistently predicted in
many H-bonding and non-bonding interactions, as indicated in Figure 56.

Figure 56. Docking scenario representing NCL I-tasser model dimerization binding mode. A. Complete
docking scenarios. B. Zoomed in version with individual residues highlighted in blue. C. Summary of
intermolecular interactions, obtained by PDBSUM. Orange, blue, and red lines represent non-bonding,
h-bonding, and salt bridge interactions, respectively
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The dimerized NCL generated from the Robetta results suggests a very different profile of
residues to constitute the interaction interface. RBD-RBD interactions were observed to be
predominant in this binding mode. The RBDs were predicted to be involved in strong bonding
interactions such as hydrogen bonds and salt bridges with the other RBDs, suggesting
interactions that increase overall stability of the complex. RBD1 and RBD4 were predicted to be
the main drivers of these interactions. Although many non-bonding interactions were predicted
to involve the RGG domain in this binding mode, their contribution to structural integrity of the
dimer was predicted to be lower than previous results from the other models. R571 from the
RBD3-4 linker was consistently predicted in all type of interactions, as indicated in Figure 57.
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Figure 57. Docking scenario representing NCL Robetta model dimerization binding mode. A. Complete
docking scenarios. B. Zoomed in version with individual residues highlighted in blue. C. Summary of
intermolecular interactions, obtained by PDBSUM. Orange, blue, and red lines represent non-bonding,
h-bonding, and salt bridge interactions, respectively
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Discussion
In this chapter we investigated oligomerization mechanisms of NCL in detail by using in silico
tools. 3D models were generated that represent domains of NCL known to be involved in
oligomerization from the literature. Docking experiments conducted with different models
generated 3 different binding modes that NCL might undergo when it dimerizes. Interestingly,
the binding modes exhibited distinct differences that could be envisioned as part of the
dimerization process with multiple steps, as indicated in Figure 58
We therefore rationalized that all 3 binding modes could potentially represent different steps
of a multistep NCL-NCL oligomerization process
1. First RGG-RGG interactions initiate NCL-NCL contact, as represented in the Intfold model
results. RBD-RBD interactions are minimal as they are positioned far away. Non-bonding
interactions are prevalent at this stage.
2. RGG-RGG interactions persist but, in this step, RGG-RBD interactions are also initiated. Even
though RBDs are pulled to each other, they are still distant enough to exhibit only limited
contact between themselves.
3. In the last step, RBDs become prominent drivers of oligomerization as RBD-RBD and RBDRGG interactions become prevalent. RBDs initiate stronger bonds with each other either
through H-bonds and salt bridges. RGG-RGG interactions are minimal here.
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Figure 58: Summary of the potential RBD-RBD oligomerization modes. A. Intfold model B. I-tasser
model C. Robetta model. RBDs are indicated in colored circles. Oligomerization interactions are
indicated in red lines.

In summary, based on our predictions, we were able to identify 3 alternative binding modes in
which RBDs and RGG domains were involved to a varying degree in all models tested. The
Robetta model suggests strong interactions between RBDs and linker regions frequently
involving hydrogen bonds and salt bridges. Therefore, they formed the most stable dimers, as
indicated in the representative binding mode in Figure 59. In this binding mode R571, N575,
R577 and S578 from RBD34 linker were predicted to establish both hydrogen bonds and salt
bridge interactions, putting an emphasis on the importance of residues in the linker region. This
observation is partially in line with our hypothesis for this chapter. NCL linker regions were
predicted by our results to be involved in NCL oligomerization modes although RBD-RBD
interactions were predicted to be dominant in this binding mode, as indicated in Figure 59. Our
results suggest that the linker regions are indeed important for NCL oligomerization, even
though they weren’t predicted to be the main drivers. It is interesting to note that the RBD3-4
linker residues were rarely predicted to be important to interactions.
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Figure 59. NCLMC Robetta model dimerization mode predicted by ClusPro. NCL1RBD is indicated in
cyan. NCL1RGG is indicated in light blue. NCL2RBD is indicated in light green. NCL2RGG is indicated in
neon green. RBD-RBD, RBD-RGG and RGG-RGG interactions are indicated in yellow, blue and red,
respectively.

Interactions of NCL dimer with p53 mRNA 3’ UTR and RPL26
It has been previously established that NCL interacts with 3’ UTR of p53 mRNA in the form of a
dimer and this results in suppression of its translation [19]. We therefore asked if an NCLMC
dimer can interact with 3’UTR of p53 mRNA. The Intfold and I-tasser dimer models were used in
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this experiment where the RBDs were available to initiate interactions with p53 mRNA. The
p53 mRNA models from the previous chapter were used in RNA-protein docking experiments.
As discussed previously in Chapter 3, RPL26 interacts with 5’ UTR of p53 and NCL competes
with RPL26 to bind to the same region. In the previous chapter we asked if NCL RBDs can
simultaneously interact with p53 and RPL26. Our results indicated that NCL was predicted to
interact with p53 mRNA using RBD1 and RBD4 and with RPL26 using RBD2 and RBD3. We
extended the question to probe if RPL26 would also bind same region on 3’ UTR that NCL was
predicted to prefer. Our docking results suggest that RPL26 was indeed also predicted to
interact with the central region on 3’ UTR that NCL was predicted to interact with, as indicated
in Figure 60A. We asked if NCLMC dimers would interact with p53 3’ UTR. Figure 60B shows a
putative scenario in which the RGG domains were predicted to interact with each other and
p53 mRNA, whereas RBDs of both NCL molecules were predicted to interact with p53 3’ UTR
molecule at its central region. The same region was predicted in our analysis from the previous
chapter as part of the monomeric NCL-p53 mRNA interaction interface.
We probed the docking analysis further to investigate if a similar interaction scenario was
possible between the NCL dimer, and RPL26 in the presence of the 3’ UTR of p53 mRNA as we
observed for p53s with monomeric NCL. Our docking results again indicated that such a
scenario is theoretically possible. Here, the RBD4 of NCL1 and RBD1 of NCL2 were predicted to
interact with p53 3’ UTR mRNA while RBD2 and RBD3 of NCL2 were predicted to interact with
RPL26 simultaneously, as indicated in Figure 60C. A negative control docking experiment with
P53l and maltose binding protein (MBP) indicated no consistency in predicted interaction
modes, as indicated in Figure 60D unlike p53 and RPL26 that preferentially recognized the
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central region of the UTR.
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Figure 60. NCL dimer interactions with RPL26, p53, and MBP. A. Representative results of RPL26
docking with p53 mRNA. RNA is indicated in orange, RPL26 is indicated in deep olive. B. Representative
results of NCLMC Intfold dimer docking with p53 mRNA. NCL1RBD is shown in cyan. NCL1RGG is shown
in hot pink, NCL2RBD is shown in green, NCL2RGG is shown in blue, mRNA is shown in orange C.
Representative results of NCLMC Intfold dimer P53l complex docked with RPL26. NCL1RBD in shown
cyan. NCL1RGG is shown in hot pink, NCL2RBD is shown in green, NCL2RGG is shown in blue, RPL is
shown in deep olive, mRNA is shown in orange. D. Representative scenarios from docking results of MBP
with P53l. MBP is shown in green. mRNA is shown in orange

In summary, the NCL homodimer was predicted to interact with both RPL26 and p53 mRNA 3’
UTR simultaneously, and since RPL26-p53 mRNA UTR interactions are critical for translational
upregulation of p53, NCL can indeed potentially suppress this process when overexpressed in
human cancers.
Oligomerization states of RBPs is an understudied topic, even though the oligomerization
process has been implicated in regulating important functions of several important RBPs. In this
chapter, although our findings described are preliminary, we have been able to generate initial
predictions that provide clues about the molecular mechanism driving NCL oligomerization and
set the stage for more detailed investigations.
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SIGNIFICANCE OF THIS STUDY
RNA binding proteins play critical roles in regulation of gene expression and manipulation of
their roles/functions frequently results in pro-tumorigenic activities. NCL is one of the most
versatile RBP with interactions with a wide range of RNA molecules. The involvement of NCLRNA interactions in a human cancer background has been studied extensively and is well
established but many questions remain unanswered. Molecular mechanisms driving these
interactions, the composition of residues driving these interactions, the type of interactions and
the physical interplay of the RNA-protein complex are vastly understudied. A traditional wet-lab
approach through site directed mutagenesis would be able to verify crucial information in
identification of most important residues driving these interactions, but without any guidance,
this approach results in a costly cycle of trial and error. This thesis is an attempt to delineate
NCL-RNA interactions using in silico tools. Our computational approach allowed us to generate
three dimensional models of NCL RBDs as well as the RNA molecules they interact with. We
used docking algorithms to generate predictions of NCL-RNA interactions, which allowed us to
investigate other important aspects of these interactions that would have been difficult to
investigate using only wet-lab based tools/methodologies. Our docking results identified 3
different binding modes with the most probable composition of NCL RBDs and the residues
found on individual RBDs driving NCL-miRNA interactions in human cancers. The analysis of our
results indicated that NCL RBD3 and RBD4 are predicted to be the main drivers of interactions
with specific nucleotides on miRNA targets of NCL. Interestingly, RBD4 was predicted to be
capable of interacting with some of the miRNA molecules just by itself although other binding
modes composed of multiple RBDs were predicted to initiate more interactions and exhibit
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lower free binding energy estimates. Investigation of NCL-mRNA UTR interactions have
revealed binding modes that comprise RBD1 and RBD4 for short molecules and RBD2, RBD3,
RBD4 or all RBDs for longer molecules. Our findings for most NCL-RNA interactions scenarios
analyzed have either not previously been reported in the literature or in other cases
corroborate experimental results. We also investigated dimerization modes of NCL, and our
results revealed that dimerization of NCL through their RGG domain is predicted to promote
interactions with p53 mRNA UTR and all RBDs were predicted to be involved in the process. In
summary, our results revealed that NCL is predicted to drive specific interactions with both primiRNA and mRNA UTR molecules using a specific subset of residues on its RBDs and these
interactions have direct impact on tumorigenic activities.
Numerous therapeutic studies have been conducted to address human cancers but the
widespread usage of chemotherapy and radiotherapy, both of which cause much harm to
patients, is a clear indicator that more specific approaches are warranted that would not wreak
havoc on the whole body but rather target specific interactions involved in tumorigenic
activities. As an example, a synthetic DNA aptamer that is expected to form G-quadruplex
structures (AS1411) with affinity towards both the RBDs and the RGG domain of NCL could
promote an inhibitory effect on its RNA binding capabilities. However, until the detailed
molecular mechanisms of the interactions are not known, such therapeutic approaches are
difficult to design. Our study provides much needed information that would pave the way
towards identification of the subset of residues involved in particular NCL -RNA interactions.
Once these residues are identified, small molecules could be developed that could mimic the
interaction interface and ultimately disrupt these interactions.
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